WO2014064058A1 - Improved process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine - Google Patents

Improved process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine Download PDF

Info

Publication number
WO2014064058A1
WO2014064058A1 PCT/EP2013/071996 EP2013071996W WO2014064058A1 WO 2014064058 A1 WO2014064058 A1 WO 2014064058A1 EP 2013071996 W EP2013071996 W EP 2013071996W WO 2014064058 A1 WO2014064058 A1 WO 2014064058A1
Authority
WO
WIPO (PCT)
Prior art keywords
trifluoromethyl
pyridin
amine
acetamide
compound
Prior art date
Application number
PCT/EP2013/071996
Other languages
French (fr)
Inventor
Dietmar Flubacher
Nicole Bieri
Murat Acemoglu
Pascal Michel
Rasmus Mose
Hans Stettler
Maria Caterina Testa
Jörg Brozio
Frank Schaefer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to US14/437,177 priority Critical patent/US9637468B2/en
Priority to IN1331DEN2015 priority patent/IN2015DN01331A/en
Priority to CN201380055482.4A priority patent/CN104736532B/en
Priority to MX2015005188A priority patent/MX360703B/en
Priority to AU2013336807A priority patent/AU2013336807B2/en
Priority to RU2015119259A priority patent/RU2646760C2/en
Priority to JP2015538398A priority patent/JP6267213B2/en
Priority to KR1020157010087A priority patent/KR102128127B1/en
Priority to ES13779841.9T priority patent/ES2605638T3/en
Priority to BR112015007243-7A priority patent/BR112015007243B1/en
Priority to CA2885471A priority patent/CA2885471C/en
Priority to EP13779841.9A priority patent/EP2912030B1/en
Publication of WO2014064058A1 publication Critical patent/WO2014064058A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Definitions

  • the present invention relates to new, improved steps in manufacturing processes for pyrimidine derivatives, to intermediates thereof and to the manufacturing of intermediates.
  • the present invention is directed to improved processes for manufacturing
  • WO 2007/084786 (priority date: January 20, 2006) describes certain pyrimidine derivatives having phosphatidylinositol 3-kinase (hereinafter referred to as "PI3K”) inhibiting properties, their use as pharmaceuticals and manufacturing processes thereof.
  • PI3K phosphatidylinositol 3-kinase
  • One pyrimidine derivative disclosed in WO 2007/084786 is the selective phosphatidylinositol 3-kinase inhibitor compound 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine, hereinafter referred to as "Compound A” or "the compound of formula A”.
  • Compound A is described in WO 2007/084786 in free form and as the hydrochloric acid salt.
  • the manufacturing process for preparing Compound A is described in Example 10 of this document.
  • the manufacturing processes described therein are, although suitable for small scale production, regarded as disadvantageous for commercial production.
  • WO International Patent Application PCT/US201 1/053808 discloses a process for manufacturing pyrimidine compounds, including Compound A, and their corresponding salts and polymorphs.
  • the process of preparing compound A and the monohydrochloride salt is summarized in Figure 1.
  • the second step of the process that leads to the boronic acid or boronic ester is complicated, with yields ranging from 30-60 %.
  • the choice of the base required to react with the acidic proton of the amide is critical and requires 5 equivalents of lithium amide in addition to 2.5 equivalents of butyl lithium at low temperature for the the Li/Br exchange reaction. Additional complications arise from precipitation of the anion. Moreover the boronic acid is unstable at high pH (> 9) and low pH ( ⁇ 1 ). The Suzuki coupling step is also complicated by the Pd catalyst required and removal of the Pd catalyst during work up.
  • the salt forming step is also complicated, as addition of more than 1 equivalent of HCI results in formation of the monohydrochloride salt of 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2- amine along with amounts of the dihydrochloride salt of 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4- trifluoromethylpyridin-2-amine, the latter salt limiting the purity of the monohydrochloride salt.
  • the invention thus provides improved methods for manufacturing Compound A, which is summarized in Figures 2-5.
  • the invention provides a process for manufacturing a compound of formula A
  • the invention also provides a process for manufacturing N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4- (trifluoromethyl)pyridin-2-yl)acetamide comprising the steps of:
  • the invention also provides a process for manufacturing N-(5-(2,6-dimorpholinopyrimidin-4-yl)- 4-(trifluoromethyl)pyridin-2-yl)acetamide comprising the step of coupling N-(5-(1 ,3,6,2- dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide and 4,4'-(6-Chloropyrimidine-2,4- diyl)di[morpholine] via a Suzuki coupling reaction wherein a palladium catalyst is generated in- situ using a mixture of Palladium(ll) acetate, triphenylphosphine and an aqueous base
  • the invention also provides a process for manufacturing a compound of formula A
  • the invention also provides a process for manufacturing a compound of formula A
  • the invention also provides a process for manufacturing a compound of formula A
  • the invention also provides an improved process for the manufacture of the salt 5-(2,6-Di-4- morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine monohydrochloride comprising the step of reacting 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine in a solution of isopropanol, water and pyridine with aqueous hydrochloric acid in isopropanol at 60° C
  • the improved manufacturing processes described herein fulfill one or more of the following criteria: safer; higher overall purity; higher yielding and more economical when compared to known processes for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine and pharmaceutically acceptable salts thereof. Further, the manufacturing processes described herein are scalable, making them suitable for commercial production.
  • FIGURE 1 outlines a process for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4- trifluoromethylpyridin-2-amine summarized in PCT/US201 1/053808.
  • FIGURE 2 summarizes one improved process for manufacturing 5-(2,6-Di-4-morpholinyl-4- pyrimidinyl)-4-trifluoromethylpyridin-2-amine.
  • FIGURE 3 summarizes an alternative improved process for manufacturing 5-(2,6-Di-4- morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine.
  • FIGURE 4 summarizes an alternative improved process for manufacturing 5-(2,6-Di-4- morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine.
  • FIGURE 5 summarizes an alternative improved process for manufacturing 5-(2,6-Di-4- morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine.
  • the compound 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine is known to have PI3K inhibiting properties. Accordingly, the compound is valuable for the treatment of various diseases, in particular for the prophylaxis or treatment of proliferative diseases. Thus, there is a great need to provide improved manufacturing methods for 5-(2,6-Di-4-morpholinyl-4- pyrimidinyl)-4-trifluoromethylpyridin-2-amine and pharmaceutically acceptable salts thereof.
  • protected with respect to hydroxyl groups, amine groups, and sulfhydryl groups refers to forms of these functionalities which are protected from undesirable reaction with a protecting group known to those skilled in the art such as those set forth in Protective Groups in Organic Synthesis, Greene, T.W.; Wuts, P. G. M., John Wiley & Sons, New Jersey, (4 th Edition, 2007) which can be added or removed using the procedures set forth therein.
  • Examples of protected hydroxyl groups include, but are not limited to, silyl ethers such as those obtained by reaction of a hydroxyl group with a reagent such as, but not limited to, t-butyldimethyl- chlorosilane, trimethylchlorosilane, triisopropylchlorosilane, triethylchlorosilane; substituted methyl and ethyl ethers such as, but not limited to methoxymethyl ether, methythiomethyl ether, benzyloxymethyl ether, t-butoxymethyl ether, 2-methoxyethoxymethyl ether, tetrahydropyranyl ethers, 1-ethoxyethyl ether, allyl ether, benzyl ether; esters such as, but not limited to, benzoylformate, formate, acetate, trichloroacetate, and trifluoroacetate.
  • a reagent such as, but not limited to
  • protected amine groups include, but are not limited to, amides such as, formamide, acetamide, trifluoroacetamide, and benzamide; imides, such as phthalimide, and dithiosuccinimide; and others.
  • protected sulfhydryl groups include, but are not limited to, thioethers such as S-benzyl thioether, and S-4-picolyl thioether; substituted S-methyl derivatives such as hemithio, dithio and aminothio acetals; and others.
  • Carboxy-protecting group refers to a carbonyl group which has been esterified with one of the commonly used carboxylic acid protecting ester groups employed to block or protect the carboxylic acid function while reactions involving other functional sites of the compound are carried out.
  • a carboxy protecting group can be attached to a solid support whereby the compound remains connected to the solid support as the carboxylate until cleaved by hydrolytic methods to release the corresponding free acid.
  • Representative carboxy-protecting groups include, for example, alkyl esters, secondary amides and the like.
  • the term "pharmaceutically acceptable salts” refers to the nontoxic acid or alkaline earth metal salts of the pyrimidine compounds of the invention. These salts can be prepared in situ during the final isolation and purification of the pyrimidine compounds, or by separately reacting the base or acid functions with a suitable organic or inorganic acid or base, respectively.
  • Representative salts include, but are not limited to, the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemi-sulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, pyridine hydrochloride, 2-hydroxyethanesulfonate, lactate, maleate, methane-sulfonate, nicotinate, 2-naphth-alenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproionate, picrate, pi
  • the basic nitrogen-containing groups can be quaternized with such agents as alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl, and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.
  • alkyl halides such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides
  • dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates
  • long chain halides such as
  • a compound does not exclude that (e.g., in a pharmaceutical formulation) more than one compound of the formula A (or a salt thereof) is present.
  • one embodiment of invention provides an improved process, as summarized in Figure 2, for manufacturing a compound of formula A
  • the one or more solvents are selected from aromatic solvents, aliphatic solvents, halogenated solvents, polar aprotic solvents, ester solvents and ethereal solvents.
  • the one or more solvents of step (a) comprises ethyl acetate and heptane and the acid anhydride is acetic anhydride.
  • Typical reaction times are in the range of 4 to 8 hours.
  • Typical reaction temperatures are in the range of 70°C to 90°C under reflux conditions.
  • acetic anhydride was continuously added within a time period of 3 hours and the reaction mixture was stirred at 80 °C for 5 hours.
  • the one or more solvents are removed in vacuo and the product was precipitated by adding additional heptane and cooling.
  • DMAP dimethylaminopyridine
  • N-(5-bromo-4-(trifluoromethyl)pyridin-2-yl)acetamide is reacted with an alkyl Grignard reagent, followed by adding a triaklylborate and by further adding 2,2'- azanediyldiethanol to form N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2- yl)acetamide in a reaction mixture comprising one or more solvents.
  • the one or more solvents are selected from aromatic solvents, aliphatic solvents, and ethereal solvents.
  • Typical alkyl Grignard reagents are selected from Ci -6 MgX (X is CI, Br, I). Typical Grignard reagents are those that can be used to perform selective metalations, namely a Grignard reagent, salt complex.
  • the alkyl Grignard reagent is isopropylmagnesiumchloride, lithium chloride complex and the one or more solvents is tetrahydrofuran and the trialkylborate is triisopropyl borate.
  • step (b) for manufacturing N-(5-(1 ,3,6,2-dioxazaborocan-2- yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide further comprises the steps of:
  • Typical reaction temperatures for step (i) are in the range of 0°C to 10°C.
  • Advantages of using an alkyl Grignard reagent is that it functions as a selective base during deprotonation and produces a stable di-anion via the transmetalation reaction.
  • the process has a further advantage over deprotonation/transmetalation using butyllithium at low temperatures in that the mono-anion does not precipitate and less equivalents of the alkyl Grignard reagent are employed as compared to the organolithium reagent for the bromide/metal exchange.
  • Typical reaction temperatures for step (ii) are in the range of 10°C to 30°C.
  • the tetrahydrofuran solvent is replaced with 2- methylterahydrofuran.
  • Typical reaction temperatures for step (iii) are in the range of 0°C to 30°C.
  • the one or more solvents are 2-methyltetrahydrofuran and
  • the boronic ester product, N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4- (trifluoromethyl)pyridin-2-yl)acetamide has several advantages over the boronic acid compound, including purity, yield and thermal stability as compared to the boronic acid.
  • N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2- yl)acetamide is coupled with 4,4'-(6-Chloropyrimidine-2,4-diyl)di[morpholine] via a palladium catalyzed Suzuki reaction comprising a catalyst, a base and one or more solvents to form N-(5- (2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide.
  • the Suzuki reaction which is utilized in many of the reactions described above, is, in principle, a known reaction in organic chemistry and denotes the palladium catalysed coupling of two reactants, wherein one of the reactants contains a reactive halide moiety and the other reactant contains a reactive boronic ester or boronic acid moiety.
  • Suitable conditions for this reaction (“Suzuki conditions") are known to those of skill in the art and relate particularly to the choice of catalyst, of diluent, of further reaction aids, of reaction times and of reaction temperatures.
  • This reaction was not yet applied using the particular starting materials as described herein, where it thus forms a new and inventive process.
  • the Pd- catalyst is Pd(PPh 3 ) 4 is generated in-situ.
  • the solvent of step (c) comprises one or more solvents selected from aromatic solvents, aliphatic solvents, halogenated solvents, polar aprotic solvents, ester solvents, ethereal solvents and water.
  • the solvent of step (c) comprises one or more solvents selected from dimethoxyethane, tetrahydrofuran, 1 ,4-dioxane, 2-methyltetrahydrofuran and water.
  • the solvent of step (c) comprises dimethoxyethane and water.
  • the solvent of step (c) comprises tetrahydrofuran and water.
  • the base of step (c) is selected from acetates, phosphates and carbonates.
  • the base of step (c) is potassium carbonate.
  • the catalyst of step (c) comprises palladium.
  • the catalyst is selected from tetrakis(triphenylphosphine)palladium(0) and bis(triphenylphosphine)palladium (II) dichloride.
  • the palladium catalyst of step (c) is formed by combining Pd(OAc) 2 with a phosphine ligand.
  • Suitable phosphine ligands are known to those of skill in the art; non-limiting examples include triphenylphosphine and tris(4-methoxy-3,5- dimethylphenyl)phosphine.
  • the catalyst of step (c) is
  • Suitable amounts of catalyst are in the range of 0.1 to 20 mol% to preferably 1 to 10 mol%.
  • Typical reaction times are in the range of 1 min to 2 days, preferably 10 min to 10 hrs, particular preferably 1 to 3 hours.
  • Typical reaction temperatures are in the range of 20°C to reflux conditions, preferably 30°C to 90°C particular preferably 40- 60°C.
  • the invention relates to a process according to process step (c) wherein the work up of the initially obtained reaction mixture comprises the steps of i) separating insoluble material (e.g., by filtering the insolubles, preferably by filtration using a filtration aid such as a celite pad), ii) separating the organic phase, and optionally replacing the solvent by another solvent (such as isopropyl acetate) iii) removing the residual palladium, and iv) crystallizing the product (preferably after aqueous acid extraction and pH controlled precipitation).
  • a filtration aid such as a celite pad
  • Suzuki catalyst can be generated in-situ and that product purification and palladium catalyst removal is carried out using extraction, with no handling of solids. Additional advantages are that steps (c) and (d) can be combined as a single process step.
  • N-(5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2- yl)acetamide is hydrolyzed in one or more solvents under acidic conditions to form the compound of formula A.
  • the solvent of step (d) comprises one or more solvents selected from aromatic solvents, aliphatic solvents, halogenated solvents, polar aprotic solvents, ester solvents, ethereal solvents and water.
  • the one or more solvents of step (d) is water.
  • the one or more solvents of step (d) is water and isopropylacetate.
  • step (d) removal of the acetyl moiety also entails replacement of this moiety with a hydrogen atom. Removal of the acetyl moiety can be performed by methods known to those of skill in the art. Non-limiting examples of such methods include acid-, base- and metal-mediated reactions. A particular example of such methods is acid-mediated hydrolysis.
  • the reagent for the removal of the acetyl moiety is selected from acids, bases and metal catalysts.
  • the reagent for the removal of the acetyl moiety is hydrochloric acid.
  • steps (a)-(d) independently comprise additional steps or procedures (e.g., to remove reaction byproducts, or to workup, isolate or purify reaction products) as detailed in the examples herein.
  • steps (a)-(d) is followed by salt formation.
  • steps (a)-(d) fulfills one or more of the following criteria: safer; simpler; higher yielding and more economical when compared to known processes for manufacturing the compound of formula A. Further, the process as described herein is considered scalable, making it suitable for commercial production.
  • the invention also provides an alternative process (Figure 3) for manufacturing a compound of formula A
  • 5-bromo-4-(trifluoromethyl)pyridin-2-amine is reacted with 3.5 equivalents of an alkyl Grignard reagent, followed by adding a triaklylborate and by further adding 2,2'-azanediyldiethanol to form N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4- (trifluoromethyl)pyridin-2-yl)amine in a reaction mixture comprising one or more solvents.
  • the one or more solvents are selected from aromatic solvents, aliphatic solvents, and ethereal solvents.
  • Typical alkyl Grignard reagents are selected from Ci -6 MgX (X is CI, Br, I).
  • Typical Grignard reagents are those that can be used to perform selective metalations, namely a Grignard reagent, salt complex.
  • the alkyl Grignard reagent is
  • isopropylmagnesiumchloride, lithium chloride complex and the one or more solvents is tetrahydrofuran and the trialkylborate is triisopropylborate.
  • N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2- yl)amine is coupled with 4,4'-(6-Chloropyrimidine-2,4-diyl)di[morpholine] via a palladium catalyzed Suzuki reaction comprising a catalyst, a base and one or more solvents to form 5- (2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine (Compound A).
  • the Suzuki reaction which is utilized in many of the reactions described above, is, in principle, a known reaction in organic chemistry and denotes the palladium catalysed coupling of two reactants, wherein one of the reactants contains a reactive halide moiety and the other reactant contains a reactive boronic ester or boronic acid moiety.
  • Suitable conditions for this reaction (“Suzuki conditions") are known to those of skill in the art and relate particularly to the choice of catalyst, of diluent, of further reaction aids, of reaction times and of reaction temperatures.
  • This reaction was not yet applied using the particular starting materials as described herein, where it thus forms a new and inventive process.
  • the Pd-catalyst is Pd(PPh 3 ) 4 .
  • the Pd-catalyst is Pd(PPh 3 ) 4 is generated in- situ.
  • the solvent of step (b) comprises one or more solvents selected from aromatic solvents, aliphatic solvents, halogenated solvents, polar aprotic solvents, ester solvents, ethereal solvents and water.
  • the solvent of step (b) comprises one or more solvents selected from dimethoxyethane, tetrahydrofuran, 1 ,4-dioxane, 2-methyl- tetrahydrofuran and water.
  • the base of step (b) is selected from acetates, phosphates and carbonates. In a particular embodiment, the base of step (b) is potassium carbonate.
  • the catalyst of step (b) comprises palladium.
  • the catalyst is selected from tetrakis(triphenylphosphine)palladium (0) and bis(triphenylphosphine)palladium (II) dichloride.
  • the palladium catalyst of step (b) is formed by combining Pd(OAc) 2 with a phosphine ligand. Suitable phosphine ligands are known to those of skill in the art; non-limiting examples include triphenylphosphine and tris(4-methoxy-3,5-dimethylphenyl)phosphine.
  • the catalyst of step (b) is tetrakis(triphenylphosphine)palladium(0).
  • Suitable amounts of catalyst are in the range of 0.1 to 20 mol% to preferably 1 to 10 mol%.
  • Typical reaction times are in the range of 1 min to 2 days, preferably 10 min to 10 hrs, particular preferably 1 to 3 hours.
  • Typical reaction temperatures are in the range of 20°C to reflux conditions, preferably 30°C to 90°C particular preferably 40-60°C.
  • steps (a) and (b) can be combined as a single step.
  • the invention also provides an alternative process ( Figure 4) for manufacturing a compound of formula A
  • N-(5-bromo-4-(trifluoromethyl)pyridin-2-yl)acetamide is reacted with 2.5 equivalents of an alkyl Grignard reagent in a reaction mixture comprising one or more solvents to form the Grignard reagent that is the dianion of N-(5-bromo-4- (trifluoromethyl)pyridin-2-yl)acetamide.
  • the one or more solvents are selected from aromatic solvents, aliphatic solvents, and ethereal solvents.
  • Typical alkyl Grignard reagents are selected from Ci -6 MgX (X is CI, Br, I).
  • Typical Grignard reagents are those that can be used to perform selective metalations, namely a Grignard reagent, salt complex.
  • the alkyl Grignard reagent is isopropylmagnesiumchloride, lithium chloride complex and the one or more solvents is tetrahydrofuran.
  • the Kumada reaction which is utilized in many of the reactions described above, is, in principle, a known reaction in organic chemistry and denotes the palladium or nickel catalysed carbon-carbon coupling of two reactants, wherein one of the reactants contains a reactive halide moiety and the other reactant contains a reactive Grignard reagent.
  • the Pd-catalyst is Pd(acetate) 2 and 1 , 1 '- Bis(diphenylphosphino)ferrocene.
  • the Pd-catalyst is NiCI 2 (dppf).
  • the solvent of step (a) comprises one or more solvents selected from ethereal solvents and water. In another embodiment, the solvent of step (a) comprises one or more solvents selected from dimethoxyethane, tetrahydrofuran, 1 ,4-dioxane, 2-methyl- tetrahydrofuran and water.
  • the palladium catalyst of step (a) is formed by combining Pd(OAc) 2 with a phosphine ligand. Suitable phosphine ligands are known to those of skill in the art; non-limiting examples include triphenylphosphine and 1 ,1 '- Bis(diphenylphosphino)ferrocene.
  • Suitable amounts of catalyst are in the range of 0.1 to 20 mol% to preferably 1 to 10 mol%.
  • Typical reaction times are in the range of 1 min to 2 days, preferably 10 min to 10 hrs, particular preferably 1 to 3 hours.
  • Typical reaction temperatures are in the range of 20°C to reflux conditions, preferably 30°C to 90°C particular preferably 40- 60°C.
  • the invention also provides an alternative process (Figure 5) for manufacturing a compound of formula A
  • N-(5-bromo-4-(trifluoromethyl)pyridin-2-yl)amine is reacted with 3.5 equivalents of an alkyl Grignard reagent in a reaction mixture comprising one or more solvents to form a Grignard reagent that the trianion of N-(5-bromo-4-(trifluoromethyl)pyridin-2- yl)amine.
  • the one or more solvents are selected from aromatic solvents, aliphatic solvents, and ethereal solvents.
  • Typical alkyl Grignard reagents are selected from Ci -6 MgX (X is CI, Br, I).
  • Typical Grignard reagents are those that can be used to perform selective metalations, namely a Grignard reagent, salt complex.
  • the alkyl Grignard reagent is
  • the Kumada reaction which is utilized in many of the reactions described above, is, in principle, a known reaction in organic chemistry and denotes the palladium or nickel catalysed carbon-carbon coupling of two reactants, wherein one of the reactants contains a reactive halide moiety and the other reactant contains a reactive Grignard reagent.
  • Suitable conditions for this reaction (“Kumada conditions") are known to those of skill in the art and relate particularly to the choice of catalyst, of diluent, of further reaction aids, of reaction times and of reaction temperatures.
  • the Pd-catalyst is Pd(acetate) 2 and 1 , 1 '-Bis(diphenylphosphino)ferrocene.
  • the Pd-catalyst is NiCI 2 (dppf).
  • the solvent of step (a) comprises one or more solvents selected from ethereal solvents and water. In another embodiment, the solvent of step (a) comprises one or more solvents selected from dimethoxyethane, tetrahydrofuran, 1 ,4-dioxane, 2-methyl- tetrahydrofuran and water.
  • the palladium catalyst of step (a) is formed by combining Pd(OAc) 2 with a phosphine ligand. Suitable phosphine ligands are known to those of skill in the art; non-limiting examples include triphenylphosphine and 1 ,1 '- Bis(diphenylphosphino)ferrocene.
  • Suitable amounts of catalyst are in the range of 0.1 to 20 mol% to preferably 1 to 10 mol%.
  • Typical reaction times are in the range of 1 min to 2 days, preferably 10 min to 10 hrs, particular preferably 1 to 3 hours.
  • Typical reaction temperatures are in the range of 20°C to reflux conditions, preferably 30°C to 90°C particular preferably 40- 60°C.
  • Aqueous hydrochloric acid in amounts from less than one, e.g. 0.94 to over one equivalent, e.g.
  • monohydrochloride salt is formed.
  • Pyridinehydrochloride acid salt ( less than 1 equivalent to 2 equivalents, e.g. 1 .1 equivalents) in an alcohol/aqueous solvent(s) can also be employed to form the monohydrochloride salt of 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4- trifluoromethylpyridin-2-amine as crystalline form A.
  • Typical elevated tempaeratures range from 25-80° C.
  • Typical solvents include for example ethanol, isopropanol, and aqueous mixtures thereof.
  • Typical concentrations of HCI used range from 0.1 N to 6N HCI, including 2.25N and 4.5 N HCI.
  • an improved process for forming the monohydrochloride salt of 5- (2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine as crystalline form A comprises adding pyridine and 1 .1 1 equivalent of 4.5 N HCI in isopropanol solution to 1 equivalent of 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine in isopropanol solution at 60° C. Crystalline form A of the monohydrochloride salt was confirmed by XRD, the XRD as disclosed in WO PCT/US201 1/053808.
  • One advantage of the improved process is that formation of the di-hydrchloride salt of 5-(2,6-Di-4-morpholinyl-4- pyrimidinyl)-4-trifluoromethylpyridin-2-amine is prevented, which acts as an impurity to the monohydrochloride salt of 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2- amine.
  • the starting materials, reaction aids used in this process step are known or obtainable in analogy to known processes.
  • the starting materials are obtained as described herein.
  • the solid forms of the compound of Formula A and its salts surprisingly possess particularly beneficial pharmacokinetic properties that make them particularly suitable for the preparation of pharmaceutical compositions comprising the compound of Formula A and salts thereof.
  • Distinct crystal forms have different physical properties such as melting points, hygroscopicities, solubilities, flow properties or thermodynamic stabilities, and, hence, distinct crystal forms allow the choice of the most suitable form for a certain use or aspect, e.g., the use as an intermediate in the process of drug manufacture or in distinct administration forms like tablets, capsules, ointments or solutions.
  • Compound A is an inhibitor of PI3K (phosphatidylinositol 3- kinase) and modulates phosphorylation of AKT in biochemical, as well as cellular assays.
  • PI3K phosphatidylinositol 3- kinase
  • Compound A and its pharmaceutically acceptable salts, and pharmaceutical compositions comprising Compound A or its pharmaceutically acceptable salt can be used for the prevention, amelioration or treatment of diseases depending on PI3K.
  • the free base of Compound A can be a solid form that exists as one or more polymorph forms, including anhydrous and hydrates.
  • the monohydrochloride salt of Compound A can be a solid form that exists as one or more polymorph forms, including anhydrous, hydrates and solvates.
  • These polymorph forms (alternatively known in the art as polymorphic forms or crystal forms) differ with respect to their X-ray powder diffraction patterns, spectroscopic, physiochemical and pharmacokinetic properties, as well as their thermodynamic stability.
  • the solid, preferably crystalline, forms of the compound of formula A, its hydrates, its salts and hydrates or solvates of its salts may preferably be used in the treatment of cellular proliferative diseases such as tumor and/or cancerous cell growth mediated by PI3K.
  • the compounds of formula A, its hydrates, its salts and hydrates or solvates of its salts are useful in the treatment of human or animal (e.g., murine) cancers, including, for example, lung and bronchus; prostate; breast; pancreas; colon and rectum; thyroid; liver and intrahepatic bile duct; hepatocellular; gastric; glioma/glioblastoma; endometrial; melanoma; kidney and renal pelvis; urinary bladder; uterine corpus; uterine cervix; ovary; multiple myeloma; esophagus; acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; brain; oral cavity and pharynx; larynx; small intestine; non-Hodgkin lymphoma;
  • human or animal cancers including, for example, lung and bronchus; prostate; breast
  • the invention relates to the use of polymorph Form A of 5-(2,6-Di-4- morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine monohydrochloride in the treatment of cancer.
  • a reactor was charged with 5-bromo-4-(trifluoromethyl)pyridin-2-amine (50 g, 207.462 mmol). Ethyl acetate (50 ml) was added and the mixture was sitrred for 10 minutes. Heptane (100 ml) was added. The mixture was warmed to 80 °C within 30 minutes. Acetic anhydride (27.404 ml, 290.446 mmol) was continuously added within a time period of 3 hours. The reaction mixture was stirred at 80 °C for 5 hours. Solvent was removed by distillation (80 °C, 750 - 550 mbar) until a residual volume of 60 ml was obtained. The mixture was cooled to 0 °C.
  • a reactor was charged with N-(5-bromo-4-(trifluoromethyl)pyridin-2-yl)acetamide (70.000 g, 247.310 mmol) and tetrahydrofuran (480.261 ml, 5861.254 mmol). The mixture was sitrred for 10 minutes. The mixture was cooled to 2 °C within 30 minutes. Isopropylmagnesiumcloride lithium chloride 1.3M in THF (197.848 ml, 247.310 mmol) was continuously added within a time period of 2 hours. The mixture was warmed to 22 °C within 30 minutes.
  • Solvent was removed by distillation at reduced pressure until a residual volume of 550 ml was obtained. An additional amount of the solvent 2-methyltetrahydrofuran (200 ml) was added at 20 °C and the mixture was stirred. The mixture was decanted and added dropwise to a second reactor charged with with 70. Og concentrated HCI (aq), 280ml brine and 300g water. The mixture was cooled to 7 °C and the pH of the mixture was adjusted to 2.97 by the addition of 148.1 g of 1 N NaOH (aq) and warmed to 20 °C and the mixture was stirred. The pH was adjusted to 3 with the addition of another 10.8 g of 1 N NaOH (aq).
  • the organic phase was separated from the aqueous phase and 500 ml of 2-methyltetrahydrofuran was added to the organic phase. Solvent was removed by distillation at reduced pressure until a residual volume of 750 ml was obtained. The azeotropic distillation of the organic phase was performed an additional two times with 2 x 500 ml of 2-methyltetrahydrofuran added to the organic phase. The 750 ml mixture was filtered and added continuously to a third reactor charged with 2,2'- azanediyldiethanol (26.001 g, 247.310 mmol) and 900ml iPrOH for 1 hour at 23 °C and the mixture was stirred.
  • N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide (25g, 78.846 mmol) was dissolved in a mixture of dimethoxyethane (200 ml.) and water (100 ml.) at 2-7°C and the solution was transferred into a jacketed, pre-cooled dropping funnel with 3°C jacket
  • the temperature of the dropping funnel is kept at 3°C.
  • the compound 4,4'-(6- chloropyrimidine-2,4-diyl)dimorpholine ( 22.45g, 78.843 mmol) and K 2 C0 3 (21 .8g, 157.7mmol) were placed in an inertized 1 L reactor and 1 ,2-dimethoxyethane (200ml_) was added, followed by the addition of water (25ml_).
  • the reactor is evacuated to 100 mbar and flushed with nitrogen two times.
  • the suspension was heated to 74-78 °C. A biphasic solution was formed.
  • N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2- yl)acetamide; 25g) was dissolved in a mixture of tetrahydrofuran (200 ml.) and water (100 ml.) at 2-5°C and the solution was transferred into a jacketed, pre-cooled dropping funnel with 3°C jacket temperature. The temperature of the dropping funnel was kept at approximately 3°C.
  • Isopropanol 60 ml. was added to the reaction mixture, followed by the addition of water (100 mL). Part of the solvent (approximately 170 mL) was distilled off at 70°C (jacket temperature) under reduced pressure starting at 800 mbar until approximately 400 mbar. Water (100 mL) was added to the mixture and another portion of solvent (approximately 10OmL) was distilled off at 70°C (jacket temperature) under reduced pressure until approximately 400 mbar. The suspension thus obtained was cooled to 25 °C and stirred for 1 hour at this temperature. The product was isolated by filtration and the filter-cake was washed with water (100 mL).
  • N-(5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide (36.1 g, 76.52 mmol) was suspended in demineralized water (180 mL). The suspension was treated with aqueous 2N HCI (180 mL) and the mixture was heated to 70°C -75°C. The reaction mixture was stirred at 75°C for 3 hours at this temperature. The reaction mixture was then cooled down to 25 °C and clear filtered. The filter cake is washed with water (2x50 mL).
  • I PA Isopropylacetate
  • pH of the biphasic solution was adjusted to 1.75 by slow addition of aq. 2N NaOH (105 g) under intense stirring. Stirring was continued for additional 15 minutes at 20-25 °C and the phases were separated. The aqueous phase was extracted with additional I PA (2x50 mL) and the phases were separated. The pH of the aqueous phase was adjusted to 9.1 by slow addition of 2N NaOH (1 14 g). A suspension was formed.
  • the product was isolated by filtration and the filter cake was washed with demineralized water (3x100 ml_). The product was dried in vacuo at 50°C over night to obtain 5-(2,6-Di-4-morpholinyl-4-pyrimidin-4-yl)-4- (trifluoromethyl)pyridin-2-amine (>99.5 a% purity as determined by HPLC) and 85% overall yield.
  • N-Acetyl-L-cystein (30.6g) was dissolved in demineralized water (300 ml.) and aqueous 4N NaOH solution (46.8 g) was added dropwise until a pH of 7.0 is achieved. 70 ml. of this solution is diluted with 210 ml. of demineralized water and the solution was used for the extractions described above.
  • the clear solution was cooled to 60°C and a first portion (1 .03 ml, 4.39 mmol, 0.2 eq.) of 4.5 N HCI in isopropanol was added.
  • the still clear solution was cooled to 55°C, seeded with 0.19 g of Form A of the monohydrochloride salt of compound A suspended in an isopropanol: water (97:2.5 w/w) mixture and stirred for 15 minutes.
  • a second portion (4.67 ml, 19.94 mmol, 0.91 eq.) of 4.5 N HCI in isopropanol was added very slowly.
  • the suspension was stirred for 60 minutes and cooled down to -10°C in 16 hours and stirred for another 60 min at -10°C.
  • the filter cake was washed with tetrahydrofuran (50 mL) and disposed.
  • the filtrate was diluted with isopropylacetate (100 mL) and the solvent was partly evaporated to a final volume of ca. 80 mL.
  • the solution was diluted with additional isopropylacetate (20 mL) and saturated aq. NaCI was added (100 mL).
  • the pH of the aqueous phase was adjusted to 5-6 with 2M HCI and water (25 mL) was added to the biphasic mixture.
  • the phases were separated and the organic phase was washed again with sat. aq. NaCI-solution.
  • aqueous phases were re-extracted with isopropylacetate (100 mL) and the organic phases were combined.
  • To the organic phase was added a solution of diethanolamine (4.4g) in tetrahydrofuran (44 mL) within 30 min.
  • the solvent was partly evaporated under reduced pressure at 35-40 °C to a final volume of ca. 100 mL.
  • the formed suspension was stirred for 30 min at room temperature and the product was isolated by filtration.
  • N-(5-(1 ,3,6,2-dioxazaborocan- 2-yl)-4-(trifluoromethyl)pyridin-2-yl)amine (2.75g, 9.99 mmol) was dissolved in a mixture of dimethoxyethane (20 mL) and 200 mL water.
  • the reaction mixture was stirred for additional 10 minutes under reflux at 95 °C.
  • the suspension was cooled down to 25 °C and stirred for 30 minutes at this temperature.
  • the product was isolated by filtration and the filter cake was washed with demineralized water (3x100 mL).
  • the product was 5-(2,6-Di-4-morpholinyl-4- pyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine, as determined by HPLC.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

The invention discloses improved processes for manufacturing a compound, 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine, its monohydrochloride salt and intermediates thereof.

Description

Improved Process for Manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4- trifluoromethylpyridin-2-amine
Field of the invention
The present invention relates to new, improved steps in manufacturing processes for pyrimidine derivatives, to intermediates thereof and to the manufacturing of intermediates. The present invention is directed to improved processes for manufacturing
5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine (Compound A, see below), the monohydrochloride salt of 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4- trifluoromethylpyridin-2-amine and intermediates thereof.
Background of the invention
WO 2007/084786 (priority date: January 20, 2006) describes certain pyrimidine derivatives having phosphatidylinositol 3-kinase (hereinafter referred to as "PI3K") inhibiting properties, their use as pharmaceuticals and manufacturing processes thereof. One pyrimidine derivative disclosed in WO 2007/084786 is the selective phosphatidylinositol 3-kinase inhibitor compound 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine, hereinafter referred to as "Compound A" or "the compound of formula A".
Figure imgf000002_0001
Compound A is described in WO 2007/084786 in free form and as the hydrochloric acid salt. The manufacturing process for preparing Compound A is described in Example 10 of this document. The manufacturing processes described therein are, although suitable for small scale production, regarded as disadvantageous for commercial production. WO International Patent Application PCT/US201 1/053808 discloses a process for manufacturing pyrimidine compounds, including Compound A, and their corresponding salts and polymorphs. The process of preparing compound A and the monohydrochloride salt is summarized in Figure 1. The second step of the process that leads to the boronic acid or boronic ester is complicated, with yields ranging from 30-60 %. The choice of the base required to react with the acidic proton of the amide is critical and requires 5 equivalents of lithium amide in addition to 2.5 equivalents of butyl lithium at low temperature for the the Li/Br exchange reaction. Additional complications arise from precipitation of the anion. Moreover the boronic acid is unstable at high pH (> 9) and low pH (<1 ). The Suzuki coupling step is also complicated by the Pd catalyst required and removal of the Pd catalyst during work up. The salt forming step is also complicated, as addition of more than 1 equivalent of HCI results in formation of the monohydrochloride salt of 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2- amine along with amounts of the dihydrochloride salt of 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4- trifluoromethylpyridin-2-amine, the latter salt limiting the purity of the monohydrochloride salt.
There is a need for improved manufacturing methods of such compounds, especially where the purity of the intermediate compounds improve the purity of the active product ingredient, Compound A and its pharmaceutically acceptable salts. In particular there is a need to provide processes that fulfill one or more of the following criteria: scalable, safer; higher overall purity; higher yielding and more economical, as compared to the process disclosed.
Summary of the invention
Accordingly, the invention thus provides improved methods for manufacturing Compound A, which is summarized in Figures 2-5.
Accordingly, the invention provides a process for manufacturing a compound of formula A
Figure imgf000004_0001
comprising the steps of:
(a) acylating 5-bromo-4-(trifluoromethyl)pyridin-2-amine to form N-(5-bromo-4- (trifluoromethyl)pyridin-2-yl)acetamide
Figure imgf000004_0002
(b) reacting N-(5-bromo-4-(trifluoromethyl)pyridin-2-yl)acetamide with an alkyl Grignard reagent followed by an triaklylborate and 2,2'-azanediyldiethanol to form N-(5-(1 ,3,6,2- dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide
Figure imgf000004_0003
(c) coupling N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide with 4,4'-(6-Chloropyrimidine-2,4-diyl)di[morpholine] via a palladium catalyzed Suzuki reaction to form N-(5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2- yl)acetamide
Figure imgf000005_0001
and
(d) hydrolyzing N-(5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2- yl)acetamide under acidic conditions to form the compound of formula A
Figure imgf000005_0002
The invention also provides a process for manufacturing N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4- (trifluoromethyl)pyridin-2-yl)acetamide comprising the steps of:
(a) reacting N-(5-bromo-4-(trifluoromethyl)pyridin-2-yl)acetamide with
isopropylmagnesiumchloride, lithium chloride in tetrahydrofuran
(b) adding tris(isopropylborate); and
(c) further adding 2,2'-azanediyldiethanol
4) water
Figure imgf000005_0003
The invention also provides a process for manufacturing N-(5-(2,6-dimorpholinopyrimidin-4-yl)- 4-(trifluoromethyl)pyridin-2-yl)acetamide comprising the step of coupling N-(5-(1 ,3,6,2- dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide and 4,4'-(6-Chloropyrimidine-2,4- diyl)di[morpholine] via a Suzuki coupling reaction wherein a palladium catalyst is generated in- situ using a mixture of Palladium(ll) acetate, triphenylphosphine and an aqueous base
Figure imgf000006_0001
The invention also provides a process for manufacturing a compound of formula A
Figure imgf000006_0002
comprising the steps of:
(a) reacting a trianion of 5-bromo-4-(trifluoromethyl)pyridin-2-amine with an triaklylborate followed by 2,2'-azanediyldiethanol to form N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4- (trifluoromethyl)pyridin-2-yl)amine
Figure imgf000006_0003
(b) coupling N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2-yl)amine with 4,4'-(6-Chloropyrimidine-2,4-diyl)di[morpholine] via a palladium catalyzed Suzuki coupling reaction to form the compound of formula A
Figure imgf000007_0001
The invention also provides a process for manufacturing a compound of formula A
Figure imgf000007_0002
comprising the steps of:
(a) coupling a Grignard reagent prepared from the dianion N-(5-bromo-4- (trifluoromethyl)pyridin-2-yl)acetamide and 4,4'-(6-Chloropyrimidine-2,4- diyl)di[morpholine] via a metal catalyzed Kumada coupling reaction to form N-(5-(2,6- dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide
Figure imgf000007_0003
and
(b) hydrolyzing N-(5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2- yl)acetamide under acidic conditions to form the compound of formula A
Figure imgf000008_0001
The invention also provides a process for manufacturing a compound of formula A
Figure imgf000008_0002
comprising the step of:
coupling a Grignard reagent prepared from the trianion of 5-bromo-4- (trifluoromethyl)pyridin-2-amine and 4,4'-(6-Chloropyrimidine-2,4-diyl)di[morpholine] via a metal catalyzed Kumada coupling reaction to form the compound of formula A
Figure imgf000008_0003
The invention also provides an improved process for the manufacture of the salt 5-(2,6-Di-4- morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine monohydrochloride comprising the step of reacting 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine in a solution of isopropanol, water and pyridine with aqueous hydrochloric acid in isopropanol at 60° C
Figure imgf000009_0001
It was discovered that the improved manufacturing processes described herein, including the particular salt forming process step, fulfill one or more of the following criteria: safer; higher overall purity; higher yielding and more economical when compared to known processes for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine and pharmaceutically acceptable salts thereof. Further, the manufacturing processes described herein are scalable, making them suitable for commercial production.
Brief description of the drawings
The foregoing aspects and many of the attendant advantages of this invention will become more readily appreciated as the same become better understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings, wherein:
FIGURE 1 outlines a process for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4- trifluoromethylpyridin-2-amine summarized in PCT/US201 1/053808.
FIGURE 2 summarizes one improved process for manufacturing 5-(2,6-Di-4-morpholinyl-4- pyrimidinyl)-4-trifluoromethylpyridin-2-amine.
FIGURE 3 summarizes an alternative improved process for manufacturing 5-(2,6-Di-4- morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine.
FIGURE 4 summarizes an alternative improved process for manufacturing 5-(2,6-Di-4- morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine. FIGURE 5 summarizes an alternative improved process for manufacturing 5-(2,6-Di-4- morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine.
Detailed Description
The compound 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine is known to have PI3K inhibiting properties. Accordingly, the compound is valuable for the treatment of various diseases, in particular for the prophylaxis or treatment of proliferative diseases. Thus, there is a great need to provide improved manufacturing methods for 5-(2,6-Di-4-morpholinyl-4- pyrimidinyl)-4-trifluoromethylpyridin-2-amine and pharmaceutically acceptable salts thereof.
The invention will be better understood and objects other than those set forth above will become apparent when consideration is given to the following detailed description thereof, including the following glossary of terms, the concluding examples and the figures. The following general definitions shall apply in this specification, unless otherwise specified:
The term "protected" with respect to hydroxyl groups, amine groups, and sulfhydryl groups refers to forms of these functionalities which are protected from undesirable reaction with a protecting group known to those skilled in the art such as those set forth in Protective Groups in Organic Synthesis, Greene, T.W.; Wuts, P. G. M., John Wiley & Sons, New Jersey, (4th Edition, 2007) which can be added or removed using the procedures set forth therein. Examples of protected hydroxyl groups include, but are not limited to, silyl ethers such as those obtained by reaction of a hydroxyl group with a reagent such as, but not limited to, t-butyldimethyl- chlorosilane, trimethylchlorosilane, triisopropylchlorosilane, triethylchlorosilane; substituted methyl and ethyl ethers such as, but not limited to methoxymethyl ether, methythiomethyl ether, benzyloxymethyl ether, t-butoxymethyl ether, 2-methoxyethoxymethyl ether, tetrahydropyranyl ethers, 1-ethoxyethyl ether, allyl ether, benzyl ether; esters such as, but not limited to, benzoylformate, formate, acetate, trichloroacetate, and trifluoroacetate. Examples of protected amine groups include, but are not limited to, amides such as, formamide, acetamide, trifluoroacetamide, and benzamide; imides, such as phthalimide, and dithiosuccinimide; and others. Examples of protected sulfhydryl groups include, but are not limited to, thioethers such as S-benzyl thioether, and S-4-picolyl thioether; substituted S-methyl derivatives such as hemithio, dithio and aminothio acetals; and others. "Carboxy-protecting group" refers to a carbonyl group which has been esterified with one of the commonly used carboxylic acid protecting ester groups employed to block or protect the carboxylic acid function while reactions involving other functional sites of the compound are carried out. In addition, a carboxy protecting group can be attached to a solid support whereby the compound remains connected to the solid support as the carboxylate until cleaved by hydrolytic methods to release the corresponding free acid. Representative carboxy-protecting groups include, for example, alkyl esters, secondary amides and the like.
As used herein, the term "pharmaceutically acceptable salts" refers to the nontoxic acid or alkaline earth metal salts of the pyrimidine compounds of the invention. These salts can be prepared in situ during the final isolation and purification of the pyrimidine compounds, or by separately reacting the base or acid functions with a suitable organic or inorganic acid or base, respectively. Representative salts include, but are not limited to, the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemi-sulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, pyridine hydrochloride, 2-hydroxyethanesulfonate, lactate, maleate, methane-sulfonate, nicotinate, 2-naphth-alenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproionate, picrate, pivalate, propionate, succinate, sulfate, tartrate, thiocyanate, p-toluene-sulfonate and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl, and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.
Where the plural form (e.g., compounds, salts) is used, this includes the singular (e.g., a single compound, a single salt). "A compound" does not exclude that (e.g., in a pharmaceutical formulation) more than one compound of the formula A (or a salt thereof) is present.
Where the singular form (e.g., solvent, base) is used, this includes the plural (e.g., solvents, bases). "A solvent", "the solvent", "a base" or "the base" does not exclude that (e.g., in a reaction mixture) more than one solvent or base is present. The salts of compounds of formula A are preferably pharmaceutically acceptable salts; such salts are known in the field.
Synthesis of 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine (Compound A)
Accordingly, one embodiment of invention provides an improved process, as summarized in Figure 2, for manufacturing a compound of formula A
Figure imgf000012_0001
comprising the steps of:
(a) acylating 5-bromo-4-(trifluoromethyl)pyridin-2-amine to form N-(5-bromo-4- (trifluoromethyl)pyridin-2-yl)acetamide
Figure imgf000012_0002
(b) reacting N-(5-bromo-4-(trifluoromethyl)pyridin-2-yl)acetamide with an alkyl Grignard reagent followed by an triaklylborate and 2,2'-azanediyldiethanol to form N-(5-(1 ,3,6,2- dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide
Figure imgf000013_0001
(c) coupling N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide with 4,4'-(6-Chloropyrimidine-2,4-diyl)di[morpholine] via a palladium catalyzed Suzuki coupling reaction to form N-(5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin- 2-yl)acetamide; and
Figure imgf000013_0002
and
(d) hydrolyzing N-(5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2- yl)acetamide under acidic conditions to form the compound of formula A.
Step (a)
In an exemplary embodiment, 5-bromo-4-(trifluoromethyl)pyridin-2-amine is acylated to form N- (5-bromo-4-(trifluoromethyl)pyridin-2-yl)acetamide in a reaction mixture comprising one or more solvents and an acid anhydride of formula (R5C=0)20, such that R5 is Ci_6 alkyl and phenyl. The one or more solvents are selected from aromatic solvents, aliphatic solvents, halogenated solvents, polar aprotic solvents, ester solvents and ethereal solvents. In one embodiment, the one or more solvents of step (a) comprises ethyl acetate and heptane and the acid anhydride is acetic anhydride. Typical reaction times are in the range of 4 to 8 hours. Typical reaction temperatures are in the range of 70°C to 90°C under reflux conditions. In one embodiment, acetic anhydride was continuously added within a time period of 3 hours and the reaction mixture was stirred at 80 °C for 5 hours. The one or more solvents are removed in vacuo and the product was precipitated by adding additional heptane and cooling. The product N-(5- bromo-4-(trifluoromethyl)pyridin-2-yl)acetamide was collected by filtration, dried under vacuum and used in step (b). Advantages of the improved process are that the solvent
dimethylaminopyridine (DMAP), previously used as a solvent in step (a) of WO International Patent Application PCT/US201 1/053808, is eliminated and that product purity is consistently high (> 99%), coupled with product yields from 94-96%.
Step (b)
In an exemplary embodiment, N-(5-bromo-4-(trifluoromethyl)pyridin-2-yl)acetamide is reacted with an alkyl Grignard reagent, followed by adding a triaklylborate and by further adding 2,2'- azanediyldiethanol to form N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2- yl)acetamide in a reaction mixture comprising one or more solvents. The one or more solvents are selected from aromatic solvents, aliphatic solvents, and ethereal solvents. Typical alkyl Grignard reagents are selected from Ci-6MgX (X is CI, Br, I). Typical Grignard reagents are those that can be used to perform selective metalations, namely a Grignard reagent, salt complex. In one embodiment, the alkyl Grignard reagent is isopropylmagnesiumchloride, lithium chloride complex and the one or more solvents is tetrahydrofuran and the trialkylborate is triisopropyl borate.
In one embodiment, the process of step (b) for manufacturing N-(5-(1 ,3,6,2-dioxazaborocan-2- yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide further comprises the steps of:
(i) reacting N-(5-bromo-4-(trifluoromethyl)pyridin-2-yl)acetamide with
isopropylmagnesiumchloride, lithium chloride in tetrahydrofuran;
(ii) adding triisopropylborate in one or more solvents; and
(iii) further adding 2,2'-azanediyldiethanol in one or more solvents.
Typical reaction temperatures for step (i) are in the range of 0°C to 10°C. Advantages of using an alkyl Grignard reagent is that it functions as a selective base during deprotonation and produces a stable di-anion via the transmetalation reaction. The process has a further advantage over deprotonation/transmetalation using butyllithium at low temperatures in that the mono-anion does not precipitate and less equivalents of the alkyl Grignard reagent are employed as compared to the organolithium reagent for the bromide/metal exchange. Typical reaction temperatures for step (ii) are in the range of 10°C to 30°C. In one embodiment, after the addition of triisopropylborate is complete, the tetrahydrofuran solvent is replaced with 2- methylterahydrofuran. Typical reaction temperatures for step (iii) are in the range of 0°C to 30°C. In one embodiment, the one or more solvents are 2-methyltetrahydrofuran and
isopropanol. The boronic ester product, N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4- (trifluoromethyl)pyridin-2-yl)acetamide has several advantages over the boronic acid compound, including purity, yield and thermal stability as compared to the boronic acid.
Step (c)
In an exemplary embodiment, N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2- yl)acetamide is coupled with 4,4'-(6-Chloropyrimidine-2,4-diyl)di[morpholine] via a palladium catalyzed Suzuki reaction comprising a catalyst, a base and one or more solvents to form N-(5- (2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide.
The Suzuki reaction, which is utilized in many of the reactions described above, is, in principle, a known reaction in organic chemistry and denotes the palladium catalysed coupling of two reactants, wherein one of the reactants contains a reactive halide moiety and the other reactant contains a reactive boronic ester or boronic acid moiety. Suitable conditions for this reaction ("Suzuki conditions") are known to those of skill in the art and relate particularly to the choice of catalyst, of diluent, of further reaction aids, of reaction times and of reaction temperatures. This reaction was not yet applied using the particular starting materials as described herein, where it thus forms a new and inventive process. In a particular embodiment of the process, the Pd- catalyst is Pd(PPh3)4 is generated in-situ.
In one embodiment, the solvent of step (c) comprises one or more solvents selected from aromatic solvents, aliphatic solvents, halogenated solvents, polar aprotic solvents, ester solvents, ethereal solvents and water. In another embodiment, the solvent of step (c) comprises one or more solvents selected from dimethoxyethane, tetrahydrofuran, 1 ,4-dioxane, 2-methyltetrahydrofuran and water. In a particular embodiment, the solvent of step (c) comprises dimethoxyethane and water. In a further particular embodiment, the solvent of step (c) comprises tetrahydrofuran and water. The base of step (c) is selected from acetates, phosphates and carbonates. In a particular embodiment, the base of step (c) is potassium carbonate. The catalyst of step (c) comprises palladium. In certain embodiments, the catalyst is selected from tetrakis(triphenylphosphine)palladium(0) and bis(triphenylphosphine)palladium (II) dichloride. In other embodiments, the palladium catalyst of step (c) is formed by combining Pd(OAc)2 with a phosphine ligand. Suitable phosphine ligands are known to those of skill in the art; non-limiting examples include triphenylphosphine and tris(4-methoxy-3,5- dimethylphenyl)phosphine. In a particular embodiment, the catalyst of step (c) is
tetrakis(triphenylphosphine)palladium(0). Suitable amounts of catalyst are in the range of 0.1 to 20 mol% to preferably 1 to 10 mol%. Typical reaction times are in the range of 1 min to 2 days, preferably 10 min to 10 hrs, particular preferably 1 to 3 hours. Typical reaction temperatures are in the range of 20°C to reflux conditions, preferably 30°C to 90°C particular preferably 40- 60°C.
In a further advantegeous embodiment, the invention relates to a process according to process step (c) wherein the work up of the initially obtained reaction mixture comprises the steps of i) separating insoluble material (e.g., by filtering the insolubles, preferably by filtration using a filtration aid such as a celite pad), ii) separating the organic phase, and optionally replacing the solvent by another solvent (such as isopropyl acetate) iii) removing the residual palladium, and iv) crystallizing the product (preferably after aqueous acid extraction and pH controlled precipitation).
Advantages of the invention are the Suzuki catalyst can be generated in-situ and that product purification and palladium catalyst removal is carried out using extraction, with no handling of solids. Additional advantages are that steps (c) and (d) can be combined as a single process step.
Step (d)
In an exemplary embodiment, N-(5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2- yl)acetamide is hydrolyzed in one or more solvents under acidic conditions to form the compound of formula A.
In one embodiment, the solvent of step (d) comprises one or more solvents selected from aromatic solvents, aliphatic solvents, halogenated solvents, polar aprotic solvents, ester solvents, ethereal solvents and water. In a particular embodiment, the one or more solvents of step (d) is water. In another particular embodiment, the one or more solvents of step (d) is water and isopropylacetate.
In step (d), removal of the acetyl moiety also entails replacement of this moiety with a hydrogen atom. Removal of the acetyl moiety can be performed by methods known to those of skill in the art. Non-limiting examples of such methods include acid-, base- and metal-mediated reactions. A particular example of such methods is acid-mediated hydrolysis. In one embodiment of step (d), the reagent for the removal of the acetyl moiety is selected from acids, bases and metal catalysts. In a particular embodiment of step (d), the reagent for the removal of the acetyl moiety is hydrochloric acid.
In certain embodiments, steps (a)-(d) independently comprise additional steps or procedures (e.g., to remove reaction byproducts, or to workup, isolate or purify reaction products) as detailed in the examples herein.
In certain embodiments, steps (a)-(d) is followed by salt formation.
The skilled practitioner will recognize several parameters of the foregoing processes that may be varied advantageously in order to obtain a desirable outcome. These parameters include, for example, the methods and means of purification of reaction components and solvents; the order of addition of said reaction components and solvents to the reaction mixture; the duration of reaction of said reaction components and solvents; and the temperature and rate of stirring, mixing or agitation of the reaction components and solvents during said reaction.
It was found that the process embodied by steps (a)-(d) (also including the particular process steps) fulfills one or more of the following criteria: safer; simpler; higher yielding and more economical when compared to known processes for manufacturing the compound of formula A. Further, the process as described herein is considered scalable, making it suitable for commercial production.
Alternative Synthesis of 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine (Compound A)
The invention also provides an alternative process (Figure 3) for manufacturing a compound of formula A
Figure imgf000017_0001
comprising the steps of:
(a) reacting 5-bromo-4-(trifluoromethyl)pyridin-2-amine with an alkyl Grignard reagent followed by an triaklylborate and 2,2'-azanediyldiethanol to form N-(5-(1 ,3,6,2- dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2-yl)amine
Figure imgf000018_0001
(b) coupling N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2-yl)amine with 4,4'-(6-Chloropyrimidine-2,4-diyl)di[morpholine] via a palladium catalyzed Suzuki coupling reaction to form the compound of formula A
Figure imgf000018_0002
Step (a)
In an exemplary embodiment, 5-bromo-4-(trifluoromethyl)pyridin-2-amine is reacted with 3.5 equivalents of an alkyl Grignard reagent, followed by adding a triaklylborate and by further adding 2,2'-azanediyldiethanol to form N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4- (trifluoromethyl)pyridin-2-yl)amine in a reaction mixture comprising one or more solvents. The one or more solvents are selected from aromatic solvents, aliphatic solvents, and ethereal solvents. Typical alkyl Grignard reagents are selected from Ci-6MgX (X is CI, Br, I). Typical Grignard reagents are those that can be used to perform selective metalations, namely a Grignard reagent, salt complex. In one embodiment, the alkyl Grignard reagent is
isopropylmagnesiumchloride, lithium chloride complex and the one or more solvents is tetrahydrofuran and the trialkylborate is triisopropylborate.
Step (b) In an exemplary embodiment, N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2- yl)amine is coupled with 4,4'-(6-Chloropyrimidine-2,4-diyl)di[morpholine] via a palladium catalyzed Suzuki reaction comprising a catalyst, a base and one or more solvents to form 5- (2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine (Compound A).
The Suzuki reaction, which is utilized in many of the reactions described above, is, in principle, a known reaction in organic chemistry and denotes the palladium catalysed coupling of two reactants, wherein one of the reactants contains a reactive halide moiety and the other reactant contains a reactive boronic ester or boronic acid moiety. Suitable conditions for this reaction ("Suzuki conditions") are known to those of skill in the art and relate particularly to the choice of catalyst, of diluent, of further reaction aids, of reaction times and of reaction temperatures. This reaction was not yet applied using the particular starting materials as described herein, where it thus forms a new and inventive process. In one embodiment of the process, the Pd-catalyst is Pd(PPh3)4. In another embodiment of the process, the Pd-catalyst is Pd(PPh3)4 is generated in- situ.
In one embodiment, the solvent of step (b) comprises one or more solvents selected from aromatic solvents, aliphatic solvents, halogenated solvents, polar aprotic solvents, ester solvents, ethereal solvents and water. In another embodiment, the solvent of step (b) comprises one or more solvents selected from dimethoxyethane, tetrahydrofuran, 1 ,4-dioxane, 2-methyl- tetrahydrofuran and water. The base of step (b) is selected from acetates, phosphates and carbonates. In a particular embodiment, the base of step (b) is potassium carbonate. The catalyst of step (b) comprises palladium. In certain embodiments, the catalyst is selected from tetrakis(triphenylphosphine)palladium (0) and bis(triphenylphosphine)palladium (II) dichloride. In other embodiments, the palladium catalyst of step (b) is formed by combining Pd(OAc)2 with a phosphine ligand. Suitable phosphine ligands are known to those of skill in the art; non-limiting examples include triphenylphosphine and tris(4-methoxy-3,5-dimethylphenyl)phosphine. In a particular embodiment, the catalyst of step (b) is tetrakis(triphenylphosphine)palladium(0). Suitable amounts of catalyst are in the range of 0.1 to 20 mol% to preferably 1 to 10 mol%. Typical reaction times are in the range of 1 min to 2 days, preferably 10 min to 10 hrs, particular preferably 1 to 3 hours. Typical reaction temperatures are in the range of 20°C to reflux conditions, preferably 30°C to 90°C particular preferably 40-60°C. In one embodiment, steps (a) and (b) can be combined as a single step.
Alternative Synthesis of 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine (Compound A)
The invention also provides an alternative process (Figure 4) for manufacturing a compound of formula A
Figure imgf000020_0001
comprising the steps of:
(a) coupling a dianion N-(5-bromo-4-(trifluoromethyl)pyridin-2-yl)acetamide and 4,4'-(6- Chloropyrimidine-2,4-diyl)di[morpholine] via a palladium catalyzed Kumada coupling reaction to form N-(5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2- yl)acetamide
Figure imgf000020_0002
and
(b) hydrolyzing N-(5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2- yl)acetamide under acidic conditions to form the compound of formula A
Figure imgf000021_0001
Step (a)
In an exemplary embodiment, N-(5-bromo-4-(trifluoromethyl)pyridin-2-yl)acetamide is reacted with 2.5 equivalents of an alkyl Grignard reagent in a reaction mixture comprising one or more solvents to form the Grignard reagent that is the dianion of N-(5-bromo-4- (trifluoromethyl)pyridin-2-yl)acetamide. The one or more solvents are selected from aromatic solvents, aliphatic solvents, and ethereal solvents. Typical alkyl Grignard reagents are selected from Ci-6MgX (X is CI, Br, I). Typical Grignard reagents are those that can be used to perform selective metalations, namely a Grignard reagent, salt complex. In one embodiment, the alkyl Grignard reagent is isopropylmagnesiumchloride, lithium chloride complex and the one or more solvents is tetrahydrofuran. The Kumada reaction, which is utilized in many of the reactions described above, is, in principle, a known reaction in organic chemistry and denotes the palladium or nickel catalysed carbon-carbon coupling of two reactants, wherein one of the reactants contains a reactive halide moiety and the other reactant contains a reactive Grignard reagent. Suitable conditions for this reaction ("Kumada conditions") are known to those of skill in the art and relate particularly to the choice of catalyst, of diluent, of further reaction aids, of reaction times and of reaction temperatures. This reaction was not yet applied using the particular starting materials as described herein, where it thus forms a new and inventive process. In one embodiment of the process, the Pd-catalyst is Pd(acetate)2 and 1 , 1 '- Bis(diphenylphosphino)ferrocene. In another embodiment of the process, the Pd-catalyst is NiCI2(dppf).
In one embodiment, the solvent of step (a) comprises one or more solvents selected from ethereal solvents and water. In another embodiment, the solvent of step (a) comprises one or more solvents selected from dimethoxyethane, tetrahydrofuran, 1 ,4-dioxane, 2-methyl- tetrahydrofuran and water. In other embodiments, the palladium catalyst of step (a) is formed by combining Pd(OAc)2 with a phosphine ligand. Suitable phosphine ligands are known to those of skill in the art; non-limiting examples include triphenylphosphine and 1 ,1 '- Bis(diphenylphosphino)ferrocene. Suitable amounts of catalyst are in the range of 0.1 to 20 mol% to preferably 1 to 10 mol%. Typical reaction times are in the range of 1 min to 2 days, preferably 10 min to 10 hrs, particular preferably 1 to 3 hours. Typical reaction temperatures are in the range of 20°C to reflux conditions, preferably 30°C to 90°C particular preferably 40- 60°C.
Alternative Synthesis of 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine (Compound A)
The invention also provides an alternative process (Figure 5) for manufacturing a compound of formula A
Figure imgf000022_0001
comprising the step of:
coupling a trianion of 5-bromo-4-(trifluoromethyl)pyridin-2-amine with 4,4'-(6- Chloropyrimidine-2,4-diyl)di[morpholine] via a palladium catalyzed Kumada coupling reaction to form the compound of formula A
Figure imgf000022_0002
In an exemplary embodiment, N-(5-bromo-4-(trifluoromethyl)pyridin-2-yl)amine is reacted with 3.5 equivalents of an alkyl Grignard reagent in a reaction mixture comprising one or more solvents to form a Grignard reagent that the trianion of N-(5-bromo-4-(trifluoromethyl)pyridin-2- yl)amine. The one or more solvents are selected from aromatic solvents, aliphatic solvents, and ethereal solvents. Typical alkyl Grignard reagents are selected from Ci-6MgX (X is CI, Br, I). Typical Grignard reagents are those that can be used to perform selective metalations, namely a Grignard reagent, salt complex. In one embodiment, the alkyl Grignard reagent is
isopropylmagnesiumchloride, lithium chloride complex and the one or more solvents is tetrahydrofuran. The Kumada reaction, which is utilized in many of the reactions described above, is, in principle, a known reaction in organic chemistry and denotes the palladium or nickel catalysed carbon-carbon coupling of two reactants, wherein one of the reactants contains a reactive halide moiety and the other reactant contains a reactive Grignard reagent. Suitable conditions for this reaction ("Kumada conditions") are known to those of skill in the art and relate particularly to the choice of catalyst, of diluent, of further reaction aids, of reaction times and of reaction temperatures. This reaction was not yet applied using the particular starting materials as described herein, where it thus forms a new and inventive process. In one embodiment of the process, the Pd-catalyst is Pd(acetate)2 and 1 , 1 '-Bis(diphenylphosphino)ferrocene. In another embodiment of the process, the Pd-catalyst is NiCI2(dppf).
In one embodiment, the solvent of step (a) comprises one or more solvents selected from ethereal solvents and water. In another embodiment, the solvent of step (a) comprises one or more solvents selected from dimethoxyethane, tetrahydrofuran, 1 ,4-dioxane, 2-methyl- tetrahydrofuran and water. In other embodiments, the palladium catalyst of step (a) is formed by combining Pd(OAc)2 with a phosphine ligand. Suitable phosphine ligands are known to those of skill in the art; non-limiting examples include triphenylphosphine and 1 ,1 '- Bis(diphenylphosphino)ferrocene. Suitable amounts of catalyst are in the range of 0.1 to 20 mol% to preferably 1 to 10 mol%. Typical reaction times are in the range of 1 min to 2 days, preferably 10 min to 10 hrs, particular preferably 1 to 3 hours. Typical reaction temperatures are in the range of 20°C to reflux conditions, preferably 30°C to 90°C particular preferably 40- 60°C.
Improved Process for Manufacturing Monohvdrochloride Salt of 5-(2,6-Di-4-morpholinyl-4- PVrimidinyl)-4-trifluoromethylpyridin-2-amine
An improved process for forming the monohydrochloride salt of 5-(2,6-Di-4-morpholinyl-4- pyrimidinyl)-4-trifluoromethylpyridin-2-amine as crystalline form A was discovered. Aqueous hydrochloric acid (in amounts from less than one, e.g. 0.94 to over one equivalent, e.g. 1.1 equivalents) in alcoholic solution in the presence of pyridine at elevated temperature when added to 1 equivalent of 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine provides the monohydrochloride salt of 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4- trifluoromethylpyridin-2-amine as crystalline form A, in high purity, with no impurities from the dihydrochloride salt of 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine. Pyridine functions to buffer amounts of HCI more than one equivalent so that a
monohydrochloride salt is formed. Pyridinehydrochloride acid salt ( less than 1 equivalent to 2 equivalents, e.g. 1 .1 equivalents) in an alcohol/aqueous solvent(s) can also be employed to form the monohydrochloride salt of 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4- trifluoromethylpyridin-2-amine as crystalline form A. Typical elevated tempaeratures range from 25-80° C. Typical solvents include for example ethanol, isopropanol, and aqueous mixtures thereof. Typical concentrations of HCI used range from 0.1 N to 6N HCI, including 2.25N and 4.5 N HCI.
In an exemplary embodiment, an improved process for forming the monohydrochloride salt of 5- (2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine as crystalline form A was discovered, that comprises adding pyridine and 1 .1 1 equivalent of 4.5 N HCI in isopropanol solution to 1 equivalent of 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine in isopropanol solution at 60° C. Crystalline form A of the monohydrochloride salt was confirmed by XRD, the XRD as disclosed in WO PCT/US201 1/053808. One advantage of the improved process is that formation of the di-hydrchloride salt of 5-(2,6-Di-4-morpholinyl-4- pyrimidinyl)-4-trifluoromethylpyridin-2-amine is prevented, which acts as an impurity to the monohydrochloride salt of 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2- amine.
The starting materials, reaction aids used in this process step are known or obtainable in analogy to known processes. Advantageously, the starting materials are obtained as described herein.
It has been found that the solid forms of the compound of Formula A and its salts surprisingly possess particularly beneficial pharmacokinetic properties that make them particularly suitable for the preparation of pharmaceutical compositions comprising the compound of Formula A and salts thereof. Distinct crystal forms have different physical properties such as melting points, hygroscopicities, solubilities, flow properties or thermodynamic stabilities, and, hence, distinct crystal forms allow the choice of the most suitable form for a certain use or aspect, e.g., the use as an intermediate in the process of drug manufacture or in distinct administration forms like tablets, capsules, ointments or solutions.
Compound A was originally described in WO2007/084786, the contents of which are
incorporated herein by reference. Compound A is an inhibitor of PI3K (phosphatidylinositol 3- kinase) and modulates phosphorylation of AKT in biochemical, as well as cellular assays.
Accordingly, Compound A and its pharmaceutically acceptable salts, and pharmaceutical compositions comprising Compound A or its pharmaceutically acceptable salt, can be used for the prevention, amelioration or treatment of diseases depending on PI3K. As described herein, the free base of Compound A can be a solid form that exists as one or more polymorph forms, including anhydrous and hydrates. The monohydrochloride salt of Compound A can be a solid form that exists as one or more polymorph forms, including anhydrous, hydrates and solvates. These polymorph forms (alternatively known in the art as polymorphic forms or crystal forms) differ with respect to their X-ray powder diffraction patterns, spectroscopic, physiochemical and pharmacokinetic properties, as well as their thermodynamic stability.
It has now been surprisingly found that under certain conditions new particular solid forms of Compound A, its hydrates, its salts and the hydrates or solvates of its salts may be found, which are described hereinafter, and which have advantageous utilities and properties
The solid, preferably crystalline, forms of the compound of formula A, its hydrates, its salts and hydrates or solvates of its salts may preferably be used in the treatment of cellular proliferative diseases such as tumor and/or cancerous cell growth mediated by PI3K. In particular, the compounds of formula A, its hydrates, its salts and hydrates or solvates of its salts are useful in the treatment of human or animal (e.g., murine) cancers, including, for example, lung and bronchus; prostate; breast; pancreas; colon and rectum; thyroid; liver and intrahepatic bile duct; hepatocellular; gastric; glioma/glioblastoma; endometrial; melanoma; kidney and renal pelvis; urinary bladder; uterine corpus; uterine cervix; ovary; multiple myeloma; esophagus; acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; brain; oral cavity and pharynx; larynx; small intestine; non-Hodgkin lymphoma;
melanoma; and villous colon adenoma. In one embodiment, the invention relates to the use of polymorph Form A of 5-(2,6-Di-4- morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine monohydrochloride in the treatment of cancer.
Examples
The following examples illustrate the invention without limiting the scope thereof. It is understood that the invention is not limited to the embodiments set forth herein, but embraces all such forms thereof as come within the scope of the disclosure.
Example 1 : Preparation of N-(5-bromo-4-(trifluoromethyl)pyridin-2-yl)acetamide
A reactor was charged with 5-bromo-4-(trifluoromethyl)pyridin-2-amine (50 g, 207.462 mmol). Ethyl acetate (50 ml) was added and the mixture was sitrred for 10 minutes. Heptane (100 ml) was added. The mixture was warmed to 80 °C within 30 minutes. Acetic anhydride (27.404 ml, 290.446 mmol) was continuously added within a time period of 3 hours. The reaction mixture was stirred at 80 °C for 5 hours. Solvent was removed by distillation (80 °C, 750 - 550 mbar) until a residual volume of 60 ml was obtained. The mixture was cooled to 0 °C. Heptane (200 ml) was added and the mixture was stirred at 0 °C for 2 hours. The product was collected by filtration. The residue was washed with heptane (25 ml) and dried in a tray dryer for 16 h at 40 °C, <20 mbar to yield 55.2 g (94.6%) of N-(5-bromo-4-(trifluoromethyl)pyridin-2-yl)acetamide as sligthly brown solid.
Example 2: Preparation of N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2- yl)acetamide
A reactor was charged with N-(5-bromo-4-(trifluoromethyl)pyridin-2-yl)acetamide (70.000 g, 247.310 mmol) and tetrahydrofuran (480.261 ml, 5861.254 mmol). The mixture was sitrred for 10 minutes. The mixture was cooled to 2 °C within 30 minutes. Isopropylmagnesiumcloride lithium chloride 1.3M in THF (197.848 ml, 247.310 mmol) was continuously added within a time period of 2 hours. The mixture was warmed to 22 °C within 30 minutes. A second addition of isopropylmagnesiumcloride lithium chloride 1.3M in THF (257.203 ml, 321.503 mmol) was continuously added within a time period of 2 hours. The mixture was stirred at 22 °C for 30 minutes after addition of the Grignard reagent was complete. Triisopropyl borate (1 16.280 g, 618.276 mmol) was added to the stirred mixture for 1 hour. Solvent was removed by distillation (20 °C, 430 - 80 mbar) until a residual volume of 550 ml was obtained. The solvent 2- methyltetrahydrofuran (500 ml) was added at 20 °C and the mixture was stirred. Solvent was removed by distillation at reduced pressure until a residual volume of 550 ml was obtained. An additional amount of the solvent 2-methyltetrahydrofuran (200 ml) was added at 20 °C and the mixture was stirred. The mixture was decanted and added dropwise to a second reactor charged with with 70. Og concentrated HCI (aq), 280ml brine and 300g water. The mixture was cooled to 7 °C and the pH of the mixture was adjusted to 2.97 by the addition of 148.1 g of 1 N NaOH (aq) and warmed to 20 °C and the mixture was stirred. The pH was adjusted to 3 with the addition of another 10.8 g of 1 N NaOH (aq). The organic phase was separated from the aqueous phase and 500 ml of 2-methyltetrahydrofuran was added to the organic phase. Solvent was removed by distillation at reduced pressure until a residual volume of 750 ml was obtained. The azeotropic distillation of the organic phase was performed an additional two times with 2 x 500 ml of 2-methyltetrahydrofuran added to the organic phase. The 750 ml mixture was filtered and added continuously to a third reactor charged with 2,2'- azanediyldiethanol (26.001 g, 247.310 mmol) and 900ml iPrOH for 1 hour at 23 °C and the mixture was stirred. Solvent was removed by distillation at reduced pressure until a residual volume of 300 ml was obtained. An additional amont of isopropanol (900 ml) was added at 20 °C and the mixture was stirred. Solvent was removed by distillation at reduced pressure until a residual volume of 300 ml was obtained. The mixture was cooled to -10 °C, and the suspended solids were collected by filtration washed with 100 ml of isopropanol at this temperature to provide 57.5 g (73.3 %) of product, N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin- 2-yl)acetamide.
Example 3: Preparation of N-(5-(2,6-dimorpholinopyrimidin-4-yl)-4(trifluoromethyl) pyridin-2-yl)acetamide
N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide (25g, 78.846 mmol) was dissolved in a mixture of dimethoxyethane (200 ml.) and water (100 ml.) at 2-7°C and the solution was transferred into a jacketed, pre-cooled dropping funnel with 3°C jacket
temperature. The temperature of the dropping funnel is kept at 3°C. The compound 4,4'-(6- chloropyrimidine-2,4-diyl)dimorpholine ( 22.45g, 78.843 mmol) and K2C03 (21 .8g, 157.7mmol) were placed in an inertized 1 L reactor and 1 ,2-dimethoxyethane (200ml_) was added, followed by the addition of water (25ml_). The reactor is evacuated to 100 mbar and flushed with nitrogen two times. The suspension was heated to 74-78 °C. A biphasic solution was formed. The solution was stirred for additional 10 minutes under reflux and a solution of triphenylphosphine (0.822g) in dimethoxyethane (15 ml_, 3.134 mmol) was added. Stirring under reflux was continued for additional 10 minutes, after which time a solution of palladiumacetate (0.176g, 0.784 mmol) in dimethoxyethane (15 ml.) was added to the refluxing reaction mixture. The reaction mixture was stirred for additional 10 minutes under reflux. To this mixture under intense stirring, the solution of N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2- yl)acetamide was added via dropping funnel for 4.5 hours, maintaining the reaction mixture at reflux and the temperature of the dropping funnel at 3°C. Intense stirring was continued for additional 15 minutes at reflux and the temperature was cooled down to 45-60 °C. Part of the solvent (270 ml.) was distilled at 45-60 °C / 125 mbar and water (200 ml.) was added in parallel. Additional solvent (100 ml.) was distilled at reduced pressure and water (100 ml.) was added in parallel. The suspension was cooled down to IT 25 °C, stirred for 30 minutes at this temperature and the precipitate was isolated by filtration. The filter cake was washed with water (2x100 ml.) and the product was dried overnight at 2 mbar/25°C to obtain 37.3g (quantitative yield) of N-(5- (2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide. The product was used as is for the next step.
In an alternative procedure, N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2- yl)acetamide; 25g) was dissolved in a mixture of tetrahydrofuran (200 ml.) and water (100 ml.) at 2-5°C and the solution was transferred into a jacketed, pre-cooled dropping funnel with 3°C jacket temperature. The temperature of the dropping funnel was kept at approximately 3°C.
4,4'-(6-Chloropyrimidine-2,4-diyl)dimorpholine; 22.45g) and K2C03 (21.8g) were placed in an inertized 1 L reactor and tetrahydrofuran (100ml_) was added, followed by the addition of water (25ml_). The biphasic mixture was stirred and heated to reflux at 80°C (jacket temperature) under stirring. The solution thus obtained was stirred for additional 10 minutes under reflux, and a solution of triphenylphosphine (1 .241 g) in tetrahydrofuran (5 ml.) was added. Stirring under reflux was continued for an additional 10 minutes, after which time a solution of
palladiumacetate (0.266g) in tetrahydrofuran (5 ml.) was added to the refluxing reaction mixture. Stirring was continued for additional 10 min at 80°C (jacket temperature) under reflux. To this mixture under intense stirring, the solution of N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4- (trifluoromethyl)pyridin-2-yl)acetamide was added via the dropping funnel during approximately 6 hours, maintaining the reaction mixture at reflux and the temperature of the dropping funnel at approximately 3°C. Intense stirring was continued for an additional 15 minutes under reflux and the temperature was cooled down to 65-70°C (jacket temperature). Isopropanol (60 ml.) was added to the reaction mixture, followed by the addition of water (100 mL). Part of the solvent (approximately 170 mL) was distilled off at 70°C (jacket temperature) under reduced pressure starting at 800 mbar until approximately 400 mbar. Water (100 mL) was added to the mixture and another portion of solvent (approximately 10OmL) was distilled off at 70°C (jacket temperature) under reduced pressure until approximately 400 mbar. The suspension thus obtained was cooled to 25 °C and stirred for 1 hour at this temperature. The product was isolated by filtration and the filter-cake was washed with water (100 mL). The product was dried over night at 50°C and 30 mbar to obtain N-(5-(2,6-dimorpholinopyrimidin-4-yl)-4- (trifluoromethyl)pyridin-2-yl)acetamide (34.39g; 96.4% crude yield). The crude product was used as is for the next step.
Example 4: Preparation of 5-(2,6-Di-4-morpholinyl-4^yrimidin-4-yl)-4(trifluoromethyl) pyridin-2-amine (Compound A)
N-(5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide (36.1 g, 76.52 mmol) was suspended in demineralized water (180 mL). The suspension was treated with aqueous 2N HCI (180 mL) and the mixture was heated to 70°C -75°C. The reaction mixture was stirred at 75°C for 3 hours at this temperature. The reaction mixture was then cooled down to 25 °C and clear filtered. The filter cake is washed with water (2x50 mL). Isopropylacetate (I PA, 100 mL) was added to the filtrate and the pH of the biphasic solution was adjusted to 1.75 by slow addition of aq. 2N NaOH (105 g) under intense stirring. Stirring was continued for additional 15 minutes at 20-25 °C and the phases were separated. The aqueous phase was extracted with additional I PA (2x50 mL) and the phases were separated. The pH of the aqueous phase was adjusted to 9.1 by slow addition of 2N NaOH (1 14 g). A suspension was formed.
Isopropylacetate (400 mL) was added to the suspension and the mixture was heated to 40 °C under stirring to obtain a biphasic solution. The phases were separated and the water phase was extracted again with isopropylacetate (50 mL). The organic phases were combined. An aqueous solution of N-Acetyl-L-cysteine (140 mL) was added to the organic phase and the mixture was stirred at 50°C for 1 hour. The phases were separated. The organic phase was treated again with an aqueous solution of N-Acetyl-L-cysteine (140 mL) for additional 1 hour at 60°C and the phases are separated. Finally, the organic phase was washed with demineralized water (70 mL) and the temperature was cooled down to 20 °C. Aqueous 1 N HCI solution (200 mL) was added slowly to the organic phase, maintaining the temperature at 20-25°C. The mixture was intensively stirred for 10 minutes and the phases were separated. The organic phase was extracted again with aqueous 1 N HCI solution (50 ml.) and with water (50 ml_). The aqueous HCI and water phases were clear filtered and combined. The pH of the combined aqueous phase was adjusted to 7.1 by slow addition of aqueous 2N NaOH solution (123 g) and the formed suspension was stirred for at least 3 hours at 20-25°C. The product was isolated by filtration and the filter cake was washed with demineralized water (3x100 ml_). The product was dried in vacuo at 50°C over night to obtain 5-(2,6-Di-4-morpholinyl-4-pyrimidin-4-yl)-4- (trifluoromethyl)pyridin-2-amine (>99.5 a% purity as determined by HPLC) and 85% overall yield.
Preparation of the N -Acetyl -L-cystein solution:
N-Acetyl-L-cystein (30.6g) was dissolved in demineralized water (300 ml.) and aqueous 4N NaOH solution (46.8 g) was added dropwise until a pH of 7.0 is achieved. 70 ml. of this solution is diluted with 210 ml. of demineralized water and the solution was used for the extractions described above.
Example 5: 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)pyridin-2-amine monohydrochloride
In a nitrogen-flushed 3 L reactor that equipped with an overhead stirrer, condenser, nitrogen inlet/outlet and 500 ml. addition funnel, 10.5 g (25.59 mmol, 1 eq.) of 5-(2,6-Di-4-morpholinyl-4- pyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine was suspended in isopropanol (79.0 g), water and pyridine (0.2 g) mixture (97:2.5:0.3 w/w/w) at room temperature. The suspension was heated to 70°C and a slightly turbid solution was obtained. The turbid solution was filtered at 70°C. The clear solution was cooled to 60°C and a first portion (1 .03 ml, 4.39 mmol, 0.2 eq.) of 4.5 N HCI in isopropanol was added. The still clear solution was cooled to 55°C, seeded with 0.19 g of Form A of the monohydrochloride salt of compound A suspended in an isopropanol: water (97:2.5 w/w) mixture and stirred for 15 minutes. A second portion (4.67 ml, 19.94 mmol, 0.91 eq.) of 4.5 N HCI in isopropanol was added very slowly. The suspension was stirred for 60 minutes and cooled down to -10°C in 16 hours and stirred for another 60 min at -10°C. The solid product was isolated by filtration and washed three times with pre-cooled isopropanol (3 x 18 g). The solid product was dried at 90°C under vacuum for at least 24 hours to afford 8.64 g (88.2% yield) of 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)pyridine-2-am
monohydrochloride as a yellow, crystalline solid, polymorph Form A.
Other monohydrochloride salt forming experiments that produce the crystalline form A monohydrochloride salt are summarized below:
Ex eriments with P ridine H drochloride
Figure imgf000031_0001
Ex eriments with P ridine
Figure imgf000031_0002
Example 6: Preparation of N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2- yl)amine
A reactor was charged with 5-bromo-4-(trifluoromethyl)pyridin-2-amine (10.000 g, 41.49 mmol) and tetrahydrofuran (44 ml). The mixture was sitrred. The mixture was cooled to 0 °C. Four equivalents of isopropylmagnesiumcloride lithium chloride 1 .3M in THF (121 .4g, 165.97mmol) was continuously added within a time period of 45 min maintaining the temperature at <10 °C. . The mixture was warmed to 44 °C after addition of the Grignard reagent was complete and stirred for 4.5h at this temperature. Triisopropyl borate (31 .85 g, 165.97mmol) in
tetrahydrofuran (32 mL) was added to the stirred mixture within 15 min and the mixture was stirred for additional 30 min at 44 °C. The mixture was cooled to 0 °C. To the mixture was added dropwise 5 N HCI (30.18 mL; 165.97mmol) in isoproanol. The mixture was warmed to 22 °C and stirred over night. The formed solid was removed by filtration, the filter cake was washed with 50 mL of tetrahydrofuran and was disposed. To the filtrate was added slowly over 45 min a solution of diethanolamine (13.22g) in tetrahydrofuran (95mL). The formed suspension was stirred 30 min and the solid was removed by filtration. The filter cake was washed with tetrahydrofuran (50 mL) and disposed. The filtrate was diluted with isopropylacetate (100 mL) and the solvent was partly evaporated to a final volume of ca. 80 mL. The solution was diluted with additional isopropylacetate (20 mL) and saturated aq. NaCI was added (100 mL). The pH of the aqueous phase was adjusted to 5-6 with 2M HCI and water (25 mL) was added to the biphasic mixture. The phases were separated and the organic phase was washed again with sat. aq. NaCI-solution. The aqueous phases were re-extracted with isopropylacetate (100 mL) and the organic phases were combined. To the organic phase was added a solution of diethanolamine (4.4g) in tetrahydrofuran (44 mL) within 30 min. The solvent was partly evaporated under reduced pressure at 35-40 °C to a final volume of ca. 100 mL. The formed suspension was stirred for 30 min at room temperature and the product was isolated by filtration. The filter cake was washed with isopropylacetate (50 mL) and dried in vacuo at room temperature to obtain 8.73 g (76.5 %) of product, N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4- (trifluoromethyl)pyridin-2-yl)amine.
Example 7: Preparation of 5-(2,6-Di-4-morpholinyl-4^yrimidin-4-yl)-4-(trifluoromethyl) pyridin-2-amine (Compound A)
The compound 4,4'-(6-chloropyrimidine-2,4-diyl)dimorpholine ( 2.85g, 9.99 mmol) and K2C03 (2.76g, 19.97 mmol) were placed in an inertized 1 L reactor and 1 ,2-dimethoxyethane (100mL) was added, followed by the addition of water (25 mL). The reactor was evacuated to 100 mbar and flushed with nitrogen two times. The suspension was heated to 60 °C. A solution of 0.1 g tetrakistriphenylphosphinepalladium in 2 mL dimethoxyethane (0.1 OOg, 0.087 mmol) was added. The suspension was heated to 78 °C and stirred for three hours. N-(5-(1 ,3,6,2-dioxazaborocan- 2-yl)-4-(trifluoromethyl)pyridin-2-yl)amine (2.75g, 9.99 mmol) was dissolved in a mixture of dimethoxyethane (20 mL) and 200 mL water. The reaction mixture was stirred for additional 10 minutes under reflux at 95 °C. The suspension was cooled down to 25 °C and stirred for 30 minutes at this temperature. The product was isolated by filtration and the filter cake was washed with demineralized water (3x100 mL). The product was 5-(2,6-Di-4-morpholinyl-4- pyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine, as determined by HPLC.
Example 8: Preparation of Trianion of 5-bromo-4-(trifluoromethyl)pyridin-2-amine using 3.5 Equivalents of Isopropylmagnesium chloride, lithium chloride complex E
Figure imgf000033_0001
A reactor was charged with 5-bromo-4-(trifluoromethyl)pyridin-2-amine (1.000 g, 4.149 mmol) and tetrahydrofuran (7.72 ml). The mixture was sitrred for 10 minutes. The mixture was cooled to 0 °C within 30 minutes. Isopropylmagnesiumcloride lithium chloride 1 .3M in THF (6.383 ml, 8.298 mmol) was continuously added within a time period of 1.5 hours at 0 °C. An additional 1.5 equivalents of isopropylmagnesiumcloride lithium chloride 1.3M in THF (4.788 ml, 6.224 mmol) was continuously added within a time period of 1 .5 hours at 0 °C. An additional 0.5 equivalents of isopropylmagnesiumcloride lithium chloride 1 .3M in THF (1 .596 ml, 2.075 mmol) was continuously added within a time period of 1 hour at 0 °C. The product was the trianion of 5-bromo-4-(trifluoromethyl)pyridin-2-amine, as determined by HPLC and LCMS.
Example 9: Preparation of 5-(2,6-Di-4-morpholinyl-4-pyrimidin-4-yl)-4- (trifluoromethyl)pyridin-2-amine (Compound A)
The compound 4,4'-(6-chloropyrimidine-2,4-diyl)dimorpholine (0.40g, 1.405 mmol), 1 ,1 '- Bis(diphenylphosphino)ferrocene (0.040g, 0.070 mmol) and Palladium acetate (0.016g, 0.070 mmol) and 2 mL of tetrahydrofuran were placed in an inertized reactor. The reactor is evacuated to 100 mbar and flushed with nitrogen two times. Isopropylmagnesiumcloride lithium chloride 1 .3M in THF (1.405 mmol) was added at 30 °C followed by an equivalent amount of the trianion of 5-bromo-4-(trifluoromethyl)pyridin-2-amine (1.405 mmol). The suspension was stirred for 0.5 hours. The product was 5-(2,6-Di-4-morpholinyl-4-pyrimidin-4-yl)-4- (trifluoromethyl)pyridin-2-amine, as determined by HPLC and LCMS.
Example 10: Preparation of the Dianion of N-(5-bromo-4-(trifluoromethyl)pyridin-2- yl)acetamide using 2.5 Equivalents of Isopropylmagnesium chloride, lithium chloride complex
A reactor was charged with N-(5-bromo-4-(trifluoromethyl)pyridin-2-yl)acetamide (1 .405 mmol) and tetrahydrofuran (2 mL). The mixture was sitrred for 10 minutes. The mixture was cooled to 0 °C within 30 minutes. Isopropylmagnesiumcloride lithium chloride 1 .3M in THF ( ml, 1.405 mmol) was continuously added within a time period of 1 hour at 0 °C. An additional 1.5 equivalents of isopropylmagnesiumcloride lithium chloride 1 .3M in THF (4.788 ml, 2.107 mmol) was continuously added within a time period of 1 .5 hours at 0 °C. The product was the dianion of N-(5-bromo-4-(trifluoromethyl)pyridin-2-yl)acetamide , as determined by HPLC and LCMS.
Example 11 : Preparation of N-(5-(2,6-dimorpholinopyrimidin-4-yl)-4- (trifluoromethyl)pyridin-2-yl)acetamide
The compound 4,4'-(6-chloropyrimidine-2,4-diyl)dimorpholine (0.40g, 1.405 mmol), 1 ,1 '- Bis(diphenylphosphino)ferrocene (0.040g, 0.070 mmol) and Palladium acetate (0.016g, 0.070 mmol) and 2 ml. of tetrahydrofuran were placed in an inertized reactor. The reactor is evacuated to 100 mbar and flushed with nitrogen two times. Isopropylmagnesiumcloride lithium chloride 1 .3M in THF (1.405 mmol) was added at 30 °C followed by an equivalent amount of the dianion of N-(5-bromo-4-(trifluoromethyl)pyridin-2-yl)acetamide (1 .405 mmol) and 1- iodoadamantane (0.413g, 1 .405 mmol). The suspension was stirred for 0.5 hours. The product was N-(5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide as determined by HPLC and LCMS.
Example 12: Preparation of N-(5-(2,6-dimorpholinopyrimidin-4-yl)-4- (trifluoromethyl)pyridin-2-yl)acetamide
The compound 4,4'-(6-chloropyrimidine-2,4-diyl)dimorpholine (0.40g, 1.405 mmol), NiCI2(dppf) 1 , 1 '-Bis(diphenylphosphino)ferrocene (0.048g, 0.070 mmol) and 2 mL of tetrahydrofuran were placed in an inertized reactor. The reactor is evacuated to 100 mbar and flushed with nitrogen two times. Isopropylmagnesiumcloride lithium chloride 1.3M in THF (1.405 mmol) was added at 30 °C followed by an equivalent amount of the dianion of N-(5-bromo-4-(trifluoromethyl)pyridin- 2-yl)acetamide (1.405 mmol). The suspension was stirred for 0.5 hours. The product was N-(5- (2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide as determined by HPLC and LCMS.

Claims

Claims
1. A process for manufacturing a compound of formula A
Figure imgf000035_0001
comprising the steps of:
(a) acylating 5-bromo-4-(trifluoromethyl)pyridin-2-amine to form N-(5-bromo-4- (trifluoromethyl)pyridin-2-yl)acetamide;
(b) reacting N-(5-bromo-4-(trifluoromethyl)pyridin-2-yl)acetamide with an alkyl Grignard reagent followed by an triaklylborate and 2,2'-azanediyldiethanol in an organic solvent to form N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide;
(c) coupling N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide with 4,4'-(6-Chloropyrimidine-2,4-diyl)di[morpholine] via a palladium catalyzed Suzuki coupling reaction to form N-(5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin- 2-yl)acetamide; and
(d) hydrolyzing N-(5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2- yl)acetamide under acidic conditions to form the compound of formula A.
2. The process of claim 1 wherein the alkyl Grignard reagent of step (b) is
isopropylmagnesium chloride lithium chloride in tetrahydrofuran and the trialkylborate is triisopropylborate.
3. The process of claim 2 wherein the palladium catalysed Suzuki coupling of step (c) comprises generating the palladium catalyst in-situ from palladium acetate and triphenylphosphine in an organic solvent.
4. The process of claim 3 wherein the hydrolysed N-(5-(2,6-dimorpholinopyrimidin-4-yl)-4- (trifluoromethyl)pyridin-2-yl)acetamide is treated with N-Acetyl-L-cystein.
5. A compound which is N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2- yl)acetamide.
6. A compound which is N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2- yl)amine.
7. A process for manufacturing a compound of formula A
Figure imgf000036_0001
comprising the steps of:
(a) reacting 5-bromo-4-(trifluoromethyl)pyridin-2-amine with an alkyl Grignard reagent followed by a triaklylborate and 2,2'-azanediyldiethanol to form N-(5-(1 ,3,6,2- dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2-yl)amine; and
(b) coupling N-(5-(1 ,3,6,2-dioxazaborocan-2-yl)-4-(trifluoromethyl)pyridin-2-yl)amine with 4,4'-(6-Chloropyrimidine-2,4-diyl)di[morpholine] via a palladium catalyzed Suzuki coupling reaction to form the compound of formula A.
8. The process according to claim 7 wherein the alkyl Grignard reagent is
isopropylmagnesiumchloride, lithium chloride in tetrahydrofuran and the palladium catalyst of step (b) is (tetrakistriphenylphosphine)palladium with an aqueous base in an organic solvent.
9. A process for manufacturing a compound of formula A
Figure imgf000037_0001
comprising the steps of:
(a) coupling a Grignard reagent prepared from the dianion N-(5-bromo-4- (trifluoromethyl)pyridin-2-yl)acetamide and 4,4'-(6-Chloropyrimidine-2,4- diyl)di[morpholine] via a metal catalyzed Kumada coupling reaction to form N-(5-(2,6- dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide; and
(b) hydrolyzing N-(5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2- yl)acetamide under acidic conditions to form the compound of formula A.
10. The process according to claim 9 wherein the dianion N-(5-bromo-4-
(trifluoromethyl)pyridin-2-yl)acetamide in step (a) is formed using 2.5 equivalents of isopropylmagnesiumchloride, lithium chloride in tetrahydrofuran and the Kumada coupling reaction is catalyzed using a metal catalyst selected from palladium acetate and 1 ,1 '-Bis(diphentlphosphino)ferrocene or NiCI2(dppf).
1 1 . A process for manufacturing a compound of formula A
Figure imgf000038_0001
comprising the step of:
coupling a trianion of 5-bromo-4-(trifluoromethyl)pyridin-2-amine and 4,4'-(6- Chloropyrimidine-2,4-diyl)di[morpholine] via a palladium catalyzed Kumada coupling reaction to form the compound of formula A.
12. The process of claim 1 1 wherein the trianion of 5-bromo-4-(trifluoromethyl)pyridin-2- amine is formed using 3.5 equivalents of isopropylmagnesiumchloride, lithium chloride in tetrahydrofuran product and the Kumada coupling reaction is catalyzed using a metal catalyst selected from palladium acetate and 1 , 1 '-Bis(diphentlphosphino)ferrocene or NiCI2(dppf).
13. A process for manufacturing a monohydrochloride salt of a compound of formula A
Figure imgf000038_0002
comprising the step of:
reacting one equivalent of 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2- amine with less than one equivalents to more than one equivalents of aqueous hydrochloride acid and pyridine in an alcohol solvent at an elevated temperature.
14. The process according to claim 13 wherein the monohydrochloride salt of 5-(2,6-Di-4- morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine is the crystalline form A.
15. The process according to claim 13 wherein 1 .2 equivalents of aqueous hydrochloride acid and 0.1 equivalents of pyridine are added to one equivalent of 5-(2,6-Di-4-morpholinyl-4- pyrimidinyl)-4-trifluoromethylpyridin-2-amine at 60° C.
16. The process according to claim 13 wherein the alcohol solvent is isopropanol.
PCT/EP2013/071996 2012-10-23 2013-10-21 Improved process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine WO2014064058A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
US14/437,177 US9637468B2 (en) 2012-10-23 2013-10-21 Process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine
IN1331DEN2015 IN2015DN01331A (en) 2012-10-23 2013-10-21
CN201380055482.4A CN104736532B (en) 2012-10-23 2013-10-21 The method of improved production 5 (2,6 24 morpholine, 4 pyrimidine) 4 trifluoromethyl pyridine, 2 amine
MX2015005188A MX360703B (en) 2012-10-23 2013-10-21 Improved process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyri midinyl)-4-trifluoromethylpyridin-2-amine.
AU2013336807A AU2013336807B2 (en) 2012-10-23 2013-10-21 Improved process for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine
RU2015119259A RU2646760C2 (en) 2012-10-23 2013-10-21 Improved method of preparing the 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethyl pyridine-2-amine
JP2015538398A JP6267213B2 (en) 2012-10-23 2013-10-21 Improved process for preparing 5- (2,6-di-4-morpholinyl-4-pyrimidinyl) -4-trifluoromethylpyridin-2-amine
KR1020157010087A KR102128127B1 (en) 2012-10-23 2013-10-21 Improved process for manufacturing 5-(2,6-di-4-morp holinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine
ES13779841.9T ES2605638T3 (en) 2012-10-23 2013-10-21 Improved Process for manufacturing 5- (2,6-di-4-morpholinyl-4-pyrimidinyl) -4-trifluoromethylpyridin-2-amine
BR112015007243-7A BR112015007243B1 (en) 2012-10-23 2013-10-21 IMPROVED PROCESS FOR MANUFACTURING 5-(2,6-DI-4-MORPHOLINYL-4-PYRIMIDINIL)-4-TRIFLUOROMETHYLPYRIDIN-2-AMINE
CA2885471A CA2885471C (en) 2012-10-23 2013-10-21 Improved process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine
EP13779841.9A EP2912030B1 (en) 2012-10-23 2013-10-21 Improved process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261717237P 2012-10-23 2012-10-23
US61/717,237 2012-10-23
US201361842101P 2013-07-02 2013-07-02
US61/842,101 2013-07-02

Publications (1)

Publication Number Publication Date
WO2014064058A1 true WO2014064058A1 (en) 2014-05-01

Family

ID=49448162

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/071996 WO2014064058A1 (en) 2012-10-23 2013-10-21 Improved process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine

Country Status (15)

Country Link
US (1) US9637468B2 (en)
EP (1) EP2912030B1 (en)
JP (1) JP6267213B2 (en)
KR (1) KR102128127B1 (en)
CN (1) CN104736532B (en)
AU (2) AU2013336807B2 (en)
BR (1) BR112015007243B1 (en)
CA (1) CA2885471C (en)
ES (1) ES2605638T3 (en)
IN (1) IN2015DN01331A (en)
MX (1) MX360703B (en)
PL (1) PL2912030T3 (en)
PT (1) PT2912030T (en)
RU (1) RU2646760C2 (en)
WO (1) WO2014064058A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957068B2 (en) 2011-09-27 2015-02-17 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
US20150353524A1 (en) * 2013-01-12 2015-12-10 Teligene Ltd Pyridine compounds used as pi3 kinase inhibitors
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
WO2016050201A1 (en) * 2014-09-29 2016-04-07 山东轩竹医药科技有限公司 High selectivity substituted pyrimidine pi3k inhibitor
US9434719B2 (en) 2013-03-14 2016-09-06 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
US9458177B2 (en) 2012-02-24 2016-10-04 Novartis Ag Oxazolidin-2-one compounds and uses thereof
WO2017028802A1 (en) * 2014-11-24 2017-02-23 苏州晶云药物科技有限公司 Crystal form of 5-[2,6-di(4-morpholinyl)-4-pyrimidinyl]-4-(trifluoromethyl)-2-pyridinamine dihydrochloride and preparation method thereof
WO2017050111A1 (en) * 2015-09-21 2017-03-30 苏州晶云药物科技有限公司 Crystal form and preparation method of 5-[2,6-di(4-morpholinyl)-4-pyrimidinyl]-4-(trifluoromethyl)-2-pyridinamine hydrochloride
US10100031B2 (en) 2014-04-22 2018-10-16 Universitaet Basel Manufacturing process for triazine, pyrimidine and pyridine derivatives

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105001151B (en) * 2015-08-28 2017-07-14 苏州明锐医药科技有限公司 Bu Panixi intermediates and preparation method thereof
CN107793394A (en) * 2017-08-03 2018-03-13 上海厚璞生物科技有限公司 A kind of serial key intermediate for producing selective PI3K inhibitor
JP2022515114A (en) * 2018-12-18 2022-02-17 アストラゼネカ・アクチエボラーグ Pharmaceutical methods and intermediates

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084786A1 (en) * 2006-01-20 2007-07-26 Novartis Ag Pyrimidine derivatives used as pi-3 kinase inhibitors
WO2012044727A2 (en) * 2010-10-01 2012-04-05 Novartis Ag Manufacturing process for pyrimidine derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4061194B2 (en) * 2001-02-08 2008-03-12 富山化学工業株式会社 6-Substituted alkylamino-3-pyridylboric acid derivatives or salts thereof and methods for producing them
EP1575940B1 (en) * 2002-11-21 2011-10-05 Novartis AG 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084786A1 (en) * 2006-01-20 2007-07-26 Novartis Ag Pyrimidine derivatives used as pi-3 kinase inhibitors
WO2012044727A2 (en) * 2010-10-01 2012-04-05 Novartis Ag Manufacturing process for pyrimidine derivatives

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957068B2 (en) 2011-09-27 2015-02-17 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
US9458177B2 (en) 2012-02-24 2016-10-04 Novartis Ag Oxazolidin-2-one compounds and uses thereof
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
US10202371B2 (en) 2012-11-12 2019-02-12 Novartis Ag Oxazolidin-2-one-pyrimidine derivatives and the use thereof as phosphatidylinositol-3-kinase inhibitors
US10173995B2 (en) * 2013-01-12 2019-01-08 Teligene Ltd. Pyridine compounds used as PI3 kinase inhibitors
US20150353524A1 (en) * 2013-01-12 2015-12-10 Teligene Ltd Pyridine compounds used as pi3 kinase inhibitors
US9434719B2 (en) 2013-03-14 2016-09-06 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
US9688672B2 (en) 2013-03-14 2017-06-27 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
US10112931B2 (en) 2013-03-14 2018-10-30 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
US10100031B2 (en) 2014-04-22 2018-10-16 Universitaet Basel Manufacturing process for triazine, pyrimidine and pyridine derivatives
US10766874B2 (en) 2014-04-22 2020-09-08 Universitaet Basel Manufacturing process for triazine, pyrimidine and pyridine derivatives
CN107001317A (en) * 2014-09-29 2017-08-01 山东轩竹医药科技有限公司 High selectivity substituted uracil PI3K inhibitor
WO2016050201A1 (en) * 2014-09-29 2016-04-07 山东轩竹医药科技有限公司 High selectivity substituted pyrimidine pi3k inhibitor
CN107001317B (en) * 2014-09-29 2019-05-24 山东轩竹医药科技有限公司 Highly selective substituted uracil PI3K inhibitor
WO2017028802A1 (en) * 2014-11-24 2017-02-23 苏州晶云药物科技有限公司 Crystal form of 5-[2,6-di(4-morpholinyl)-4-pyrimidinyl]-4-(trifluoromethyl)-2-pyridinamine dihydrochloride and preparation method thereof
WO2017050111A1 (en) * 2015-09-21 2017-03-30 苏州晶云药物科技有限公司 Crystal form and preparation method of 5-[2,6-di(4-morpholinyl)-4-pyrimidinyl]-4-(trifluoromethyl)-2-pyridinamine hydrochloride

Also Published As

Publication number Publication date
US20150246897A1 (en) 2015-09-03
CN104736532A (en) 2015-06-24
AU2013336807A1 (en) 2015-03-05
BR112015007243A2 (en) 2017-07-04
IN2015DN01331A (en) 2015-07-03
CA2885471C (en) 2021-02-23
MX360703B (en) 2018-11-14
RU2015119259A (en) 2016-12-20
RU2646760C2 (en) 2018-03-07
EP2912030A1 (en) 2015-09-02
CA2885471A1 (en) 2014-05-01
KR102128127B1 (en) 2020-06-30
AU2016238941A1 (en) 2016-11-03
JP2016502510A (en) 2016-01-28
AU2013336807B2 (en) 2016-10-27
CN104736532B (en) 2017-04-05
KR20150072408A (en) 2015-06-29
PT2912030T (en) 2016-11-30
MX2015005188A (en) 2015-09-07
EP2912030B1 (en) 2016-08-31
PL2912030T3 (en) 2017-02-28
US9637468B2 (en) 2017-05-02
BR112015007243B1 (en) 2022-02-08
JP6267213B2 (en) 2018-01-24
ES2605638T3 (en) 2017-03-15

Similar Documents

Publication Publication Date Title
AU2013336807B2 (en) Improved process for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine
EP2235001B1 (en) Process for preparing pyridinone compounds
IL281292B2 (en) Processes for the preparation of a diarylthiohydantoin compound
EP2608791B1 (en) A process for the preparation of imatinib base
AU2016387566A1 (en) An improved process for the preparation of Regorafenib
CN111943930B (en) Synthesis process of Lasmidinan
WO2014020467A2 (en) Process for the preparation of pyrazole substituted aminoheteroaryl compounds
US7714127B2 (en) Process for making heteroaryl amine intermediate compounds
TW200922923A (en) Process for producing toluidine compound
CN108473510B (en) Process for preparing 2-pyrazolo [1,5-a ] pyrazin-2-ylpyrido [1,2-a ] pyrimidin-4-one
TWI685485B (en) Processes to produce acalabrutinib
WO2015163446A1 (en) Method for producing imidazole compound
JP2006001889A (en) Bactericidal pyridine compound
WO2012052444A1 (en) Process for the preparation of nicotinamide derivatives
JP2011526257A (en) Process for producing N-phenyl-N- (4-piperidinyl) amide salt
JP2021075535A (en) Chemical process for preparing pyrimidine derivatives and intermediates thereof
JP2019196359A (en) Chemical process for preparing pyrimidine derivatives and intermediates thereof
CA3214107A1 (en) New process for the synthesis of 5-{5-chloro-2-[(3s)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1h)- carbonyl]phenyl}-1,2-dimethyl-1h-pyrrole-3-carboxylic acid derivatives and its application for the production of pharmaceutical compounds
AU2003249262A1 (en) Process for the preparation of imidazo(1,2-a)pyridine-3-acetamides
WO2023187833A1 (en) A novel salt of bempedoic acid
JP5080050B2 (en) Method for producing optically active piperazine compound
WO2007086559A1 (en) Method for producing tetrahydropyran compound
JP2018131415A (en) Method for producing l-carnosine derivative and its salt

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13779841

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2013336807

Country of ref document: AU

Date of ref document: 20131021

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2885471

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2013779841

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013779841

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015007243

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20157010087

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14437177

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2015538398

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/005188

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2015119259

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112015007243

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150331